

CURRICULUM VITAE (Version 7/2025)

NAME: **WELLS A. MESSERSMITH, MD, FACP, FASCO**

TITLE: Professor (with Tenure) of Medicine
Head, Division of Medical Oncology, Dept of Medicine
Chief Medical Officer, Oncology Services (UCHealth)
Associate Director for Clinical Services
University of Colorado Cancer Center (UCCC)

WORK ADDRESS: University of Colorado School of Medicine
Division of Medical Oncology
Department of Medicine

CLINICAL ADDRESS Anschutz Cancer Pavilion
University of Colorado Hospital

EDUCATION: 1992, B.A., Williams College *summa cum laude* Highest
honors in Biology; Honors in Music Williamstown,
Massachusetts
1998, M.D., Harvard Medical School
Boston, Massachusetts
1998-2001, Internship and Residency (Internal Medicine)
Massachusetts General Hospital/Harvard Medical
School Boston, Massachusetts
2001-2004, Fellowship, Medical Oncology
2002-2004, Fellowship, Drug Development
Johns Hopkins University, Department of Oncology
Baltimore, Maryland

ACADEMIC APPOINTMENTS

2004-2007 Assistant Professor, Johns Hopkins School of Medicine
Baltimore, Maryland
2007-2012 Associate Professor, University of Colorado School of Medicine
Aurora, Colorado

2012-present Professor (with tenure), University of Colorado School of Medicine
 2007-2017 Director, GI Medical Oncology, University of Colorado Cancer Center
 (position passed to mentee, Chris Lieu, in 2017)
 2008-2012 Deputy Head, Division of Medical Oncology
 2009-2018 co-Leader, Developmental Therapeutics Program, Cancer Center
 2012-2013 Co-Head, Division of Medical Oncology
 2013-present National Director, Academic GI Cancer Consortium (AGICC)
 2014-present Head, Division of Medical Oncology, Department of Medicine
 University of Colorado School of Medicine
 2016-2017 Director, Phase I Program, University of Colorado Cancer Center
 2017-2022 Associate Director for Translational Research, Cancer Center
 2020-2023 COVID Official, Medical Oncology
 2022-present Associate Director for Clinical Services, UCCC
 Chief Medical Officer, Oncology Services, UCHealth

OTHER PREVIOUS PROFESSIONAL APPOINTMENTS

1991 Research Assistant, Williams College, Department of Molecular Biology
 Williamstown, Massachusetts
 1992-1993 Biologist (GS-7), Food and Drug Administration, Center for Biologics Evaluation
 and Research, National Institutes of Health, Bethesda, Maryland (summers)
 1993 Research Assistant, Center for Neuroscience, University College London
 London, United Kingdom
 1995 Research Assistant, Center for Neurologic Disease, Harvard Medical School
 Boston, Massachusetts
 1998-2001 Research Assistant, Medical Practices Evaluation Unit, MGH, Harvard Medical
 School, Boston, Massachusetts

HONORS AND AWARDS

2025 Named to *Coe Atherton Endowed Chair in Pancreatic Cancer Research*
 2024 Appointed to the NCI Board of Scientific Advisors
 2024 Distinguished Faculty Professionalism Award, School of Medicine
 2024 Gail Jackson Award, Johns Hopkins Kimmel Cancer Center
 2021 National Leader, NCI/CTEP GI Disease-Focused Clinical Investigators
 2021-22 Chair, ASCO Leadership Development Program (Alexandria, VA)
 2019 Appointed "Fellow of the American Society of Clinical Oncology" (FASCO)
 2019 Presidential Citation for Meritorious Service, University of Colorado
 Hospital (Aurora, CO)
 2018 NCI Cancer Therapy Evaluation Program "Michaele Christian Oncology
 Development Award and Lectureship" (Rockville, MD)
 2011 American Society of Clinical Oncology Leadership Development Program
 2009 National Cancer Institute Clinical Investigator Team Leadership Award
 2008 Elected to Fellowship of American College of Physicians (FACP)
 2005 Passano Clinician Scientist Award, Johns Hopkins School of Medicine
 2004 Amgen Oncology Institute Heme-Onc Career Development Award
 2004 American Society of Clinical Oncology Young Investigator Award
 2004 American Society of Clinical Oncology GI Symposium Merit Award
 2003 American Society of Clinical Oncology Merit Award
 2004 First Prize in Clinical Research, Fellow Research Day, Sidney Kimmel
 Comprehensive Cancer Center at Johns Hopkins

2001	Outstanding Service Award, Massachusetts General Hospital Residency Program
1998	Harvard Medical School, Kurt Isselbacher Humanitarian Award for "research, teaching, and compassionate patient care"
1993	Astor Research Fellowship, University College London, United Kingdom
1993	Arthritis Foundation Research Fellow, National Institutes of Health
1992	Williams College, <i>summa cum laude</i>
1992	Williams College, Phi Beta Kappa (as a Junior and Senior)
1992	Williams College, Hagedorn Prize for Outstanding Premedical Student
1992	Williams College, Conant-Harrington Prize in Biology (outstanding thesis)
1192	Williams College, Kleinhandler Prize for Excellence in Music
1992	Williams College, Canby Athletic Scholarship Prize (highest athlete GPA)
1992	Williams College, Class of 1960 Scholar in Biology

CLINICAL HONORS

2012-present	Named nearly yearly as "Top Doctor in Denver" in 5280 Magazine Also named in <i>Castle Connolly Top Doctors</i> , <i>Best Doctors</i> , <i>COLORADOBIZ Best Doctors</i> , etc
--------------	--

POST-GRADUATE COURSES

2002	"Methods in Clinical Cancer Research" AACR/ASCO Workshop (Vail, CO)
2002	"Clinical Pharmacology of Anticancer Agents" Cancer Education Consortium (Leesburg, VA)
2002-2004	"Pharmacokinetics/Pharmacodynamics Lecture Series" Johns Hopkins Cancer Center (Baltimore, MD)
2002-2003	"Science of Clinical Evaluation", 2002-2003 (Baltimore, MD) Johns Hopkins Bloomberg School of Public Health "Methods in Clinical Research", 2002 "Statistical Methods in Clinical Research", 2002 "Outcomes Research", 2003 "Ethical and Regulatory Issues in Research", 2003
2003	Molecular Biology in Clinical Oncology AACR Workshop (Aspen, CO)
2011-12	ASCO "Leadership Development Program" (Alexandria, VA)
2017-18	Leadership Development Program, University of Colorado School of Medicine
2019-20	Mentor, ASCO "Leadership Development Program" (Alexandria, VA)
2020-21	Chair, ASCO "Leadership Development Program" (Alexandria, VA)
2024-25	"Collective Leadership Program", Department of Medicine, University of Colorado

PROFESSIONAL ORGANIZATIONS

PROFESSIONAL SOCIETIES

1998-present	American College of Physicians; Fellow as of 2008
1998-2001	Massachusetts Medical Society, Committee on Ethnic Diversity
2001-present	American Society of Clinical Oncology
2001-present	American Association for Cancer Research
2009-present	Rocky Mountain Oncology Society - Board of Directors, 2011; 2017-present - President, 2012-2014 - Board of Directors/Immediate Past President, 2015-2016

COMMITTEE AND SERVICE RESPONSIBILITIES

NATIONAL COMMITTEES (see below for NIH grant review committees)

- 2004-2007 Eastern Cooperative Oncology Group
Gastrointestinal and Developmental Therapeutics Committees
Role: Member and local Principal Investigator of Eastern Cooperative Oncology Group trials
- 2005-2007 National Comprehensive Cancer Network
Myeloid Growth Factor Committee
Role: Member
- 2006-2012 & 2017-2023 Investigational Drug Steering Committee Task Force on Signal Transduction; Cancer Therapy Evaluation Program, National Cancer Institute
Role: Member
- 2007-2009 Scientific Program Committee, Gastrointestinal - Colorectal Cancer Tract American Society of Clinical Annual Meeting
Role: Member (2008, 2010; 2017-2019)
Role: chair (2009, 2018)
- 2007-2021 Gastrointestinal Committee, Southwestern Oncology Group
Role: co-Chair, Colon Cancer sub-committee (2014-present)
- 2007-2009 Expert Panel on Radiation Oncology-Rectal/Anal Cancer American College of Radiology, ACR Appropriateness Criteria
Role: Member
- 2008-2009 Best of American Society of Clinical Oncology Committee
Role: Chair, Gastrointestinal – Colorectal Tract (2009)
- 2009-2011 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Program Committee
2010 Role: Member and session moderator
2011 Role: Chair, colorectal committee; Chair, translational session
- 2009-2012 American Society of Clinical Oncology Integrated Technology Committee
Role: Member
- 2010-present U.S. Colon Cancer Task Force
Role: Member (R01 holder)
- 2010-2014 U.S. Gastrointestinal Steering Committee
Role: Member (R01 holder)
- 2011-2015 Phase II Consortium (P2C)
Role: Director, Gastrointestinal Cancer Program
- 2012-2015 ASCO Lifelong Learning Committee
Role: Member; CME Subcommittee Liaison
- 2012-2013 AACR Annual Meeting 2013 Scientific Program Committee
Role: Member, Clinical Trials in Progress Subcommittee
- 2012-2013 ASCO/ASCP/CAP/AMP Evaluation of Molecular Markers for Colorectal Cancer
Role: Member
- 2013-2018 American Board of Internal Medicine (ABIM)
Role: Member, Medical Oncology Committee
- 2013-present National Comprehensive Cancer Network (NCCN)
Role: Member, Committee on Colon/Rectal/Anal Cancers (national guidelines)
- 2013-present National Comprehensive Cancer Network (NCCN)
Role: Member, Investigator Steering Committee
Role: Guidelines Steering Committee (2021-present)

2014-2016	Chair, Therapeutics Committee, ASSIGN phase III clinical trial Member, Steering Committee, ASSIGN trial
2014-2015	co-Chair, Translational Medicine, SouthWest Oncology (SWOG) GI Committee
2014-2022	co-Chair, Colon Cancer sub-committee, SWOG GI Committee
2018-present	Member, Vanderbilt GI SPORE External Advisory Board
2019-present	Member, NCCN Value-Based Pathways Committee (GI cancers)
2020-2022	Member, ABIM Approval Committee
2020-present	Member, Mayo GI SPORE External Advisory Board
2023	Chair, LianBio Scientific Advisory Board
2023-present	Member, ASCO Scientific Program Committee, GI/Colorectal
2024-present	co-Leader, NCI/CTEP Pidnarulex Project Team (ETCTN) (mentee: Lentz)
2024-present	Member, IDSC Signal Transduction Target Working Group
2023-present	Member, ASCO Oncology Medical Home Learning Collaborative
2024-2025	Chair, ASCO Scientific Program Committee, GI-Colorectal
2024-2025	Member, ASCO Education Committee, GI-Colorectal
2024-present	Member, NCI Board of Scientific Advisors (BSA)

INSTITUTIONAL COMMITTEES

	University of Colorado Anschutz Medical Campus (grant review committees listed below)
2025	Member, Tenure Review Committee, Department of Dermatology
2025	Physician Lead, UCHealth Genomic Governance Group
2025	Member, Department of Ob/Gyn Chair Search Committee
2024	Member, Tenure Review Committee, Department of Pharmacology
2024-present	Chair, Initiatives Subcommittee, Clinical Outcomes Governance Group (COGG)
2024-present	co-Chair, Oncology Quality Oversight Committee
2024-present	Member, Division of Medical Oncology Quality Council
2023-present	Member, Internal Advisory Board, Rady Center of Excellence
2023-present	Member, Cancer QI Committee
2023-present	Member, UCHealth Research Council
2023-present	Chair, UCH/SOM Cell-Based Therapies Steering Committee
2023-present	Chair, SOM/Cancer Center Molecular Diagnostics Steering Committee
2023-present	Member, UCH Cell-Based Therapy Executive Committee
2023-present	Member, Infusion Steering Committee
2023-present	Member, Anschutz Medical Campus Lab Research Forum
2022-2023	Chair, Search Committee, Cardiology Division Head
2022-present	Member, UCCC Cell Technology Shared Resource Advisory Board
2021-present	Chair, Integrated Network Cancer Program (INCP)
2021-present	co-Chair, UCCC/UCHealth Joint Operating Committee (JOC)
2021-present	co-Chair, Oncology Clinical Outcomes Governance Group (COGG)
2022-present	Member, UCCC Shared Resource Oversight Committee
2020-2022	Member, Selection Committee, Dean's Distinguished Seminar Series
2021	Member, Seligman Chair Review Committee
2021-present	Member, Flatiron Joint Steering Committee (UCCC/UCHealth)
2021-2023	Member, Human Immunology and Immunotherapy Initiative Director's Group
2020-2021	Member, Search Committee, Director, Thoracic Oncology Research Initiative
2020-2021	Member, Search Committee, Executive Director, Cancer Center (SOM/UCHealth)
2020	Member, Search Committee, Chief Research Officer (SOM/UCHealth)
2020	Member, Search Committee, Director of Head & Neck Surgery, Department of Otolaryngology
2018-2019	Member, Investigative Committee, Medical Staff Office (given a UCHealth "service award" for this work)

2018-2022 co-Chair, Immunotherapy Task Force, University of Colorado Hospital
 2018-2020 Chair, Selection Committee, Dean's Distinguished Seminar Series
 2018-2019 Member, Search Committee, Division Head for Gastroenterology
 2017-present Member, Dean's Advisory Committee, School of Medicine
 2016-2017 Member, Search Committee, Thoracic Oncology Research Initiative
 2015-2016 Member, Search Committee, Division Head, Pulmonary/Critical Care
 Department of Medicine
 2015-present Member, Molecular Pathology Shared Resource
 Internal Advisory Board
 2014-present Member, Department of Medicine Promotions Committee
 Associate to Full Professor (with Tenure)
 2013-2014 Member, Search Committee, Molecular Pathologist/CMOCO
 2013-2014 Member, Search Committee, Psychologist, Solid Tumor Service
 2013-2014 Academic Clinical Enterprise: Vision 2018
 Leadership Council
 2013-2014 Academic Clinical Enterprise: Vision 2018
 Oncology Subcommittee
 2013-2014 Search Committee, Molecular Pathology/CMOCO co-Director
 Role: member
 2012-2013 Clinical Task Force (SOM visioning process) / Relationships Subcommittee
 Role: member
 2012-2014 Search Committee, VA GI section head
 Role: member
 2012-present Protocol Review and Monitoring Committee
 Role: Ad Hoc Member/Reviewer
 2011-2013 Search Committee, University of Colorado School of Medicine
 Division Head, Hematology
 Role: Member
 2011-2012 University of Colorado Hospital "Lone Tree Satellite" Planning Committee
 Role: Member
 2011-2014 University of Colorado School of Medicine/University of Colorado Hospital
 Research Advisory Committee
 Role: Member
 2011-2014 University of Colorado Cancer Center/Radiology Steering Committee
 Role: Member
 2011-2015 Search Committee, University of Colorado Cancer Center Associate Director for
 Prevention and Control
 Role: Member
 2011-2013 Clinical and Research Survivorship Program Committee
 Role: Member
 2011-2013 Colorado Cancer Registry Special Project Advisory Board
 Role: Member
 2008-present Biobanking Work Group
 Role: Member
 2009-2013 Search Committee, Biostatistics/Bioinformatics Core Director
 Role: Member
 2008-2009 IMPAC workgroup
 Role: Member
 2008-2009 EPIC/cancer center implementation committee
 Role: Member
 2008-2009 Treatment Flow Workgroup

- 2008-present Role: Member
Junior Faculty Advisory Committees
Lauren Fishbein, M.D., Ph.D. 2017-2019
Colin Weekes, M.D., Ph.D. (K12), 2007-2017
Antonio Jimeno, M.D., Ph.D., 2009-2016
Stephen Leong, M.D. (K12), 2007-2016
Karl Lewis, M.D., 2007-2016
Erica Bradshaw Pierce, PhD, 2007 - 2013
Dan LeBarbera, PhD (DoD CDA), 2009 - 2016
Christopher Lieu, MD (K12, K23), 2009-2017
Liz Kessler, MD, 2015-2020
Todd Pitts, PhD, 2016-2021
Lindsey Davis, MD, 2013-2021
Alexis Leal, MD, 2017 – present
Gentry King, MD, 2016-2019
Heather Leach, PhD, 2017-present
Rob Lentz, MD 2022 - present
- 2007-2017 University of Colorado Cancer Center Space Committee
Role: Member
- 2007-2008 Adjudication Committee, Beta-Blocker Evaluation of Survival Trial
University of Colorado Cancer Center
Role: Voting Member
- 2009-2011 University of Colorado Hospital Tower Planning Committee
University of Colorado Cancer Center Expansion Committee
Role: Member
- Johns Hopkins University School of Medicine
- 2009-2007 Johns Hopkins University/Johns Hopkins Kimmel Cancer Center
Oncology Strategic Planning Committee
Role: Ad Hoc Member
- 2006-2007 Pharmacy and Therapeutics Committee
Johns Hopkins Hospital
Role: Voting Member
- 2006-2007 Chemotherapy Subcommittee, Pharmacy and Therapeutics Committee
Sidney Kimmel Comprehensive Cancer Center / Johns Hopkins Hospital
Role: co-Chair
- 2006-2007 Ad Hoc Committee on Insurance Clearance for Clinical Trials
Sidney Kimmel Comprehensive Cancer Center / Johns Hopkins Hospital
Role: co-Chair
- 2005-2007 Data Safety and Monitoring Committee
Department of Oncology, Johns Hopkins University
Role: Voting Member
- 2006-2007 Pharmaquip Professional Advisory Committee
Johns Hopkins Hospital
Role: Member
- 2004-2007 Department of Oncology, Johns Hopkins University
Treatment Flow Workgroup
Role: co-Chair
- 2002-2004 Department of Oncology, Johns Hopkins University
Education Committee
Role: Representative, leader of Morbidity and Mortality Conference

2002-2004 Department of Oncology, Johns Hopkins University
 Critical Care Committee
 Role: Fellow Representative

DATA SAFETY MONITORING BOARDS

2022-present Data Safety Monitoring Board (DSMB)
 “FORTITUDE-101 and -102: Bemarituzumab in FGFR2b Overexpressing
 GEJ Adenocarcinoma”
 Role: Member

2021-present Data Safety Monitoring Board (DSMB)
 “FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided
 Colorectal Cancer”
 Role: Member

2020-present Data Safety Monitoring Board (DSMB)
 “A Phase 2b, open-label, single-arm study of ZW25 monotherapy in
 subjects with advanced or metastatic HER2-amplified biliary tract cancers”
 Role: Chair

2018-present Data Safety Monitoring Board (DSMB)
 “FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study
 Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously
 Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3
 Preceded by Dose-Finding in Phase 1” (FivePrime Therapeutics)
 Role: Member

2018-present Data Monitoring Committee (DMC)
 “ARI-AT-002: Phase 2 Trial of Brigatinib after Treatment with Next-
 Generation ALK inhibitors in Refractory ALK Rearranged NSCLC”
 (Academic Thoracic Oncology Medical Investigators Consortium)
 Role: Member

2017-present Data Monitoring Committee (DMC)
 “A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and
 Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in
 Subjects with Unresectable or Recurrent Gastric or Gastroesophageal
 Junction Adenocarcinoma” (GS-US-296-2013)
 Role: Member

2015-2016 Independent Data Safety Monitoring Board
 “IMMU-107-04 (‘An International, Multi-Center, Double-Blind, Randomized,
 Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose
 Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with
 Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least
 Two Prior Treatments (PANCRIT-1)’”
 Role: Chair

2014-2016 Independent Data Safety Monitoring Board
 “GS-US-370-1296 entitled ‘A Phase 2, Randomized, Double-blind Study of
 Gemcitabine and Nab paclitaxel combined with Momelotinib in Subjects
 with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
 Preceded by a Dose-finding, Lead-in Phase’”
 Role: Member

2014-2016 Independent Data Safety Monitoring Board
 “ALPINE: A Phase 1b/2 Study of OMP-59R5 in Combination with
 NabPaclitaxel and Gemcitabine in Subjects with Previously Untreated
 Stage IV Pancreatic Cancer”

- 2010-2012 Role: Chair
Independent Data Safety Monitoring Board
“MEK113487: A Randomized, Double-blind Placebo Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine subjects with Metastatic Pancreatic Cancer”
- 2008-2012 Role: Chair
Independent Data Safety Monitoring Board
“A Phase II Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of MORAb-009 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer” (sites in US, Canada, Spain, Argentina, Belgium)
- 2009-2011 Role: Member
Independent Data Safety Monitoring Board
“An Open-label Clinical Trial of MORAb-009 in Combination with Pemetrexed and Cisplatin in Subjects with Mesothelioma”
Role: Member

INSTITUTIONAL CONFERENCES

- 2002-2003 Department of Oncology, Johns Hopkins University
Morbidity and Mortality Conference
Role: Conference Organizer and Leader
Monthly multi-disciplinary conference to review monthly morbidity, mortality, and safety
- 2007-2016 Colorado Cancer Day / Rocky Mountain Cancer Conference
2007: Faculty lecturer, “Colorectal Cancer: Chemotherapy and Beyond”
2008: Course Director: 150 participants, 30 speakers, Continuing Medical Education (7 credit hours)
2009: Faculty Lecturer, Colorectal Cancer Block (Continuing Medical Education and patient information)
2012: Chair, Colorectal Cancer Block
2013: Faculty Lecturer, Colorectal Cancer Block (Continuing Medical Education)
2016: Faculty Lecturer, Colorectal Cancer Block
- 2018 Rocky Mountain Interventional Endoscopy Course Lecturer
2023-present Course Director, CME Multi-Disciplinary Conferences, UCHealth

COMMUNITY SERVICE

- 2004-present Media/Advocacy about Gastrointestinal cancers and drug development
Colorado Sun new article on Cancer Pharmacogenomics (2/26/2024)
Channel9 News interview for World Cancer Day 2024 (2/5/2024)
Wings of Hope 5K for Pancreatic Cancer Research (11/4/2023)
(interviewed for Kool105 Radio story on ACS/Making Strides Event, 7/18/2023)
(Interviewed for Scripps/Denver Ch7 story on Drug Discovery Center, 9/30/21)
(Scripps interview ran on >60 networks nationally)
(lecturer, Cherry Creek High School, “Diagnosing/Treating Cancer”, 2018-2023)
(speaker, Lustgarten Walk for Pancreatic Cancer, 11/3/2019)
(speaker, “Wings of Hope Pancreatic Cancer Fundraiser” 9/28/2019)
(participant, AACR/ACC “Hill Day”, visited US Congress, 5/30/2019)
(speaker, “Lustgarten Cancer Research Foundation” 5k 11/4/2018)
(speaker, “Wings of Hope Pancreatic Cancer Fundraiser” 11/17/2017)

- (grant review committee, Wings of Hope Pancreatic Cancer, 7/8/2017)
 (speaker, "Wings of Hope Pancreatic Cancer Fundraiser" 10/27/2016)
 (participant, "Undy5000" race for colorectal cancer; 6/25/2016)
 (interviewed for podcast, "immunotherapy for GI cancers," 4/4/2016)
 (Interviewed on Channel 7 for story on colorectal cancer, 2/2016)
 (speaker, roundtable between Cancer Research Institute/Fightcolorectalcancer
 "Immunotherapy for Colorectal Cancer" Overview" NY, NY 12/2/2015)
 (organizer/speaker, Research Advocacy Training Program;
 Fightcolorectalcancer.org; "Reviewing Grant Proposals" 11/6/2015)
 (participant, "Ray of Hope" relay team, Colfax Marathon; 5/17/2015)
 (participant, "Scope it Out" race for colorectal cancer; 10/4/2014)
 (participant, "PanCan PurpleStride Run/Walk" 4/27/2014)
 (interviewed on Denver Channel 7 for PurpleStride, 4/24/2014)
 (participant, "UNDY5000" race for colorectal cancer; 6/2013)
 (interviewed for Denver Channel 7, "Exercise and Cancer", 5/2013)
 (interviewed in-studio/on-air for Denver Channel 7 re: colorectal screening,
 3/2011)
 (interviewed for Denver Channel 7 story on colorectal patient getting chemo,
 3/2011)
 (quoted in Altitude Media Radio story on participation in clinical trials, 12/2010)
 (quoted in media release on clinical trial of hedgehog inhibitor, 11/2010)
 (30 minute interview on Gastrointestinal American Society of Clinical Oncology,
 Upper Gastrointestinal Malignancies, via Imidex, 2/2010)
 (quoted in on-air interview on phase I study, Channel 7, 12/2009)
 (quoted in MedScape article on KRAS and colon cancer, 10/2009)
 (quoted on-camera Fox31 News on anal cancer, 6/2009)
 (quoted in Cure Magazine on carcinoma of unknown primary, 6/2009)
 (quoted in Financial Times (FT.Com) on KRAS testing, 1/2009)
 (quoted in curetoday.com article on KRAS testing, 10/2008)
 (interviewed for Video News Release: "Colorectal Cancer in Young Adults",
 10/2008)
 (on-air Channel 2, quoted as course director of Colorado Cancer Day, 9/2008)
 (quoted in CURE article on colorectal cancer and KRAS testing, 9/2008)
 (quoted in University of Colorado Hospital insider: "Gastrointestinal
 Multidisciplinary Clinic", 8/2008)
 (quoted on MedPage Today, "American Society of Clinical Oncology: oxaliplatin
 gives survival edge for colon cancer", 6/2008)
 (on-air TV interview, Channel 2, "screening for colon cancer", 3/2008)
 (on-air TV interview, Channel 2, "pancreas cancer", 3/2008)
 (quoted in Longmont Times article on colon hydrotherapy, 1/2008)
 (quoted in Denver Post front page article on anal cancer, 9/2007)
 (quoted in Washington Post series on activist patient, 10/2006)
 (quoted in Associated Press article on colon cancer, 12/2005)
- 2004-2007 Lecturer, Johns Hopkins Patient Information Day on Colon Cancers
 "Understanding Chemotherapy for Colon Cancer"
 Panelist, Question and Answer Sessions
- 2005 Lecturer, "Topics in Targeted Therapies" Patient Information Day
 "Targeted Therapies in Colorectal Cancer"
- 2006 Lecturer, Johns Hopkins "A Woman's Journey" Patient Information Day
 "Screening and Treatment of Colon Cancer"
- 2007-2008 Colorado Cancer Day (see above)

	Lecture, "Colorectal Cancer: Chemotherapy and Beyond" (2007)
	Course Director (2008): 150 participants, 30 speakers, Continuing Medical Education (7 credit hours)
2010-2011	Volunteer Member, Cancer League of Colorado Grants Review Committee
2011	Speaker, Colon Cancer Alliance Annual Meeting (Denver, CO; 6/24/2011) "New Treatment Options for Colorectal Cancer: What is on the Horizon?"
2013	Speaker, UCCC Showcases (4/15/2013; 1/30/2014) "How Philanthropy Can Help the GI/Phase I Cancer Programs" (4/2013) Moderator, "Pancreas Cancer Care at UCCC" (1/2014)
2014	Team Leader, PanCan "Purple Stride" fundraiser (for pancreas cancer)
2014	Speaker, UCCC Community Engagement Event (Lone Tree, CO) "Chemotherapy for Colorectal Cancer" (4/28/2014)
2015	Speaker, "Wings of Hope" Pancreas Cancer Funds Dedication Ceremony
2015	Speaker, Community Research Advocates Training Program
2015	Speaker, FightColorectal Cancer Immunology Meeting

LICENSURE AND BOARD CERTIFICATION

2007-present	Colorado State Medical License
2001-2015	Maryland State Medical License
2000-2003	Massachusetts State Medical License
2004-present	Diplomate in Medical Oncology
2001-2011	Diplomate in Internal Medicine
2000-present	U.S. DEA

PATENTS HELD AND PENDING

Jimeno A, Messersmith W, and Hidalgo M, "A Method for Identifying Responsiveness of Tumors to Pharmacological Agents" (JHU-5170) 1/11/2007

Vasilis Vasiliou, Ying Chen, Bettina Miller, Antonio Jimeno, Messersmith W, and David C. Thompson "Small Molecule Aldehyde Dehydrogenase Inhibitors and Methods of Use Thereof" Provisional Application No. 62/084,830; Filed: 11/26/2014; CU TTO File No. CU3609H-PPA1

REVIEW AND REFEREE WORK (see below for NCI)

2005	Auditor, Theradex Inc (National Cancer Institute/Cancer Therapy Evaluation Program)
2005-present	Reviewer, <i>Cancer Chemotherapy and Pharmacology</i>
2004-present	Reviewer, <i>American Journal of Clinical Oncology</i>
2006-present	Reviewer, <i>Clinical Cancer Research</i>
2006-present	Reviewer, <i>Molecular Cancer Therapeutics</i>
2006-present	Reviewer, <i>Journal of Clinical Oncology</i>
2007-present	Reviewer, Wellpoint Medical Policy
2007-present	Reviewer, <i>Biologics: Targets and Therapy</i>
2008	Protocol Reviewer, <i>Swiss Group for Clinical Cancer Research</i>
2008-present	Reviewer, <i>Clinical Colorectal Cancer</i>
2008-present	Reviewer, <i>British Journal of Cancer</i>
2008-present	Reviewer, <i>American Society of Clinical Oncology Annual Meeting Summaries</i>
2008-present	Reviewer, <i>The Oncologist</i>

2009-present Member, Peer Review Board, American College of Physicians
 2010-present Reviewer, *ACP Medicine*
 2010-present Reviewer, *Cancer Journal: The Journal of Principles and Practice of Oncology*
 2012-present Reviewer, *Clinical Investigation*
 2012-present Reviewer, *New England Journal of Medicine*
 2013-present Reviewer, *Journal of the National Comprehensive Cancer Network*
 2014-present Reviewer, *Journal of Clinical Oncology*
 2014-present Reviewer/Auditor, University of Colorado Cancer Registry
 2012-present CME Auditor, ASCO/AGA/SSO GI Symposium
 2013-2019 Member, ABIM Medical Oncology Subcommittee
 2020-2024 Member, ABIM Approval Committee

GRANT REVIEWS (see below for NIH/NCI Review Committees)

2005 Reviewer, Samsung Medical Center Grant, Baltimore, Maryland
 2007-present Reviewer, American Cancer Society IRG/University of Colorado Cancer Center Seed Grants
 2009-2012 Reviewer, ASCO Career Development Award
 Reviewer, ASCO Young Investigator Award
 2010-2012 Reviewer, Scientific Advisory Board, Cancer League of Colorado
 Chair (2012), Scientific Advisory Board
 2011-present Reviewer, University of Colorado Cancer Center
 Pilot Grants Program (ACS, Wings of Hope, Golfers Against Cancer, Cancer League of Colorado)
 2015 Reviewer, Cancer Prevention and Control Pilot Grants Program
 2015-present Reviewer, Developmental Therapeutics Pilot Grant Program
 2016 Reviewer, University of Colorado Digestive and Liver Diseases
 Pilot / Feasibility and High Impact Awards
 2018-2022 Reviewer, ASCO Leadership Development Program
 2022 Member, review committee, CU – CSU Joint Pilot Projects in Companion
 Animals in Cancer Research

GRANT REVIEW COMMITTEES (NCI, DOD, Cancer Center)

2020-present Reviewer, NCI Cancer Center Support Grant (CCSG)
 NCI-A RTRB-G (E2). ZRG1 CPDT-M (40) P
 Role: Reviewer (2020, 2021, 2022, 2025)
 2021 Reviewer, NCI SPORE (P50) Special Emphasis Panel
 ZCA1 RPRB-8 (J1, M1, etc)
 Role: Discussion Leader, Reviewer
 Also: 2020, Discussion Leader (DL); 2019 (DL), 2018 (DL)
 2017 (DL)
 2016 Reviewer, NCI Special Emphasis Panel (NCI/NIH)
 2017/01 ZCA1 RPRB-7 (J1): NCI Barrett's Esophagus Translational
 Research Network Review
 Role: Discussion Leader, reviewer
 2016 National Institutes for Health/ National Cancer Institute
 Reviewer, NCTN Core Correlative Sciences Committee (NCTN-CCSC)
 2016 National Institutes for Health/ National Cancer Institute
 Reviewer, Provocative Questions
 PQ4: Why do some closely related tissues exhibit dramatically different

- cancer incidence?
Role: Reviewer
- 2016 National Institutes for Health/ National Cancer Institute
ZCA1 SRB-C (M1): NCI Omnibus R03 & R21 SEP-2 Review Committee
Role: Reviewer
- 2015 National Institutes for Health/ National Cancer Institute
ZCA1 SRB-C (J1): NCI Omnibus R03 & R21 SEP-2 Review Committee
Role: co-Chair and Reviewer
- 2015 National Institutes for Health/ National Cancer Institute
NCI F Institutional Training and Education Grants
Role: Reviewer (R25, T32, K12)
- 2015 Department of Defense, VA Merit Award Review Panel
2015/08 ONC-C
Role: Reviewer
- 2015 National Institutes for Health/ National Cancer Institute
2015/05 ZCA1 SRB-C (M1) S
Omnibus SEP-2 (R21 and R03)
Role: Reviewer
- 2014 National Institutes for Health/ National Cancer Institute
2014/10 ZCA1 SRB-C (O1) S
Omnibus SEP-6 (R21 and R03)
Role: Reviewer
- 2013 National Institutes for Health/National Cancer Institute
2014/01 Council ZCA1 SRLB-C J1 R.
Provocative Questions: Cancer Therapy and Outcomes
Role: Reviewer
- 2013 National Institutes for Health/National Cancer Institute
2013/05 NCI-J. Subcommittee J - Career Development
Role: Reviewer
- 2011-2012 National Institutes for Health/National Cancer Institute
ZCA1 SRLB-1 (O1) R
Barrett's Esophagus Translational Research Network
Role: Reviewer
- 2011-present National Institutes for Health/National Cancer Institute
ZCA1 PCRB-A (A1) B
Clinical Research- Loan Repayment Program
Role: Reviewer
- 2011-2013 University of Colorado Cancer Center
Tobacco-Related Lung Cancer Grants
Role: Reviewer
- 2011-present University of Colorado School of Medicine Lung Cancer SPORE Project
Proposals
Role: Reviewer
- 2011-2012 National Institutes for Health/National Cancer Institute
ZCA1 RPRB-M (M1, J1) P
SPORE in Prostate, Skin, Pancreatic and other Gastrointestinal Cancers
Role: - Ad Hoc Member/Reviewer (9/2011; 6/2011; 2/2012)
- Discussion Leader, 2/2012; 5/2012
- 2009-2012 American Society of Clinical Oncology Cancer Foundation Young
Investigator Award/Career Development
Award Selection Committee

2009-2012 Role: Member/Reviewer; 2011, Executive Committee Member
 Scientific Advisory Board / Grant Reviewer
 Cancer League of Colorado

2009-present Role: Chair, 2011; Member/Reviewer, 2009-2010
 University of Colorado Cancer Center
 Pilot Project Review Committee
 Role: Reviewer

TEACHING RECORD

Teaching: Fellowship Development

- Director, "Gastrointestinal Cancer Clinical/Translational Research Fellowship Program" (2010)
 This is a program (approved by GMEC) which aims to provide additional specialized training in the management of gastrointestinal cancers as well as translational research.

- Director, "Drug Development Fellowship Program" (2017-2020)
 This is a program (approved by GMEC) which aims to provide additional specialized training in cancer drug development.

- Director, CME Courses for UCH Multi-Disciplinary Clinics (500 yearly) (2023-present)
 This program permits CME credit for ~10 Multi-Disciplinary Clinics weekly at UCH, which includes participants from UCH and satellite clinics/hospitals.

Teaching: Clinical Instruction

Tutor, Harvard Medical School (HMS), Patient/Doctor I Course, 1996-1998
 Resident Instructor, HMS, Patient/Doctor II Course, 1999-2001
 Fellow Supervision (monthly), Johns Hopkins Medical Oncology Clinic, 2004-2007
 Cancer Education Consortium, Pharmacology of Anticancer Agents, Lecturer, 2004-2007
 Johns Hopkins International, "Oncology Videoconferences", co-Director and Presenter, 2005-2007
 Medical Oncology Fellow Supervision, Outpatient/Inpatient, UCSOM, 2007-present
 Intern/Resident Supervision, Outpatient/Inpatient, UCSOM, 2007-present
 Preceptor, "Foundations of Doctoring" (MSTP), UCSOM, IDPT7655, 2008-2009, 2014-2015, 2018-2019, 2019-2021

Teaching: Multidisciplinary Fellowship (Johns Hopkins)

Fellowship Coordinator, Medical Oncology Rotation, Surgical Oncology Fellowship, 2006-2007
 Johns Hopkins School of Medicine, Baltimore, MD

Teaching: Mentorship (National Level)

2010; 2015; 2017 Faculty, American Society of Clinical Oncology Gastrointestinal Special Session: Fellows, Residents, and Junior Faculty Networking Luncheon (San Francisco, CA)

2010-2011 Faculty, American Society of Clinical Oncology Fellows/Junior Faculty Program

2011-2016 Faculty, "Mock Study Section for Fellows and Junior Faculty" American Society of Clinical Oncology Annual Meeting (Chicago, IL)

2019-2020 Mentor/Group Leader, ASCO Leadership Development Program

2019-2020 NCI Diversity Career Development Program (DCDP)- faculty mentor

2021-2022 Chair, Mentor/Group Leader, ASCO Leadership Development Program

2021 Mentor and Clinical Preceptor, ASCO Oncology Scholars Rotation (ASCO program designed for under-represented minority medical students)
 Discussion Group Leader, Immunotherapy

Teaching: Medical School Classroom Instruction

2014-2020	University of Colorado School of Medicine (Aurora, CO) Applied Clinical Pharmacology Course (MEDS 8029). "Management of Colorectal Cancer"
2005-2007	Oncology Fellows Lecture Series, Johns Hopkins (Baltimore, MD) "Overview of Colorectal Cancer Treatment" (yearly) "Writing Chemotherapy Orders" (yearly) "Finding a Job after Fellowship" (yearly)
2004	Johns Hopkins Medical School Pathobiology Course (2 nd year), Discussion Leader, 2004 Pathobiology of Neoplasia (Year II), Section Leader, 2005-2006

STUDENTS AND RESIDENTS (clinic shadowing)

Name	Date	Prior Position	Current Position
Audrey Chan, MD	2005-2006	Premedical Student	Medical Student, Johns Hopkins
Joni Maeda, PharmD	2005	Pharmacy Resident	Oncology Pharmacist
Xiahua Yan, MD	2005-2006	M.D. Graduate	Resident
Parastoo Fazeli, MD	2006-2007	Resident	Chief Resident
Judith Nwachuku,PhmD	2006-2007	Pharmacy Resident	Oncology Pharmacist
Gretchen Taylor, MD	2007	Premedical Student	Medical Student, Univ of Nevada
Rebecca Powell, PA	2008-2011	Premedical Student	Clinical Research Coordinator
Basel Touban, MA	2008-2009	Premedical Student	Medical Student, NY Medical College
Kevin Quackenbush,MD	2010-2013	Premedical Student	Anesthesia Resident
Jacqi Reineman, MD	2010-2011	Premedical Student	Research Assistant (summer)
Anna Goldberg, MD	2014-2016	Medical Student	Medical Student, Univ CO (SOM)
Justin Greene, MD	2014-2016	Medical Student	Medical Student, Univ CO (SOM)
Macy Mingus	2015-2017	Doctoral Student	Doctoral Student, Univ CO (SOP)
Josh Abbott, PhD	2017-2020	Doctoral Student	NCATS

PRECEPTOR, "FOUNDATIONS OF DOCTORING" IDPT7655 COURSE (MSTP)

Name	Date	Prior Position	Current Position
Max Cohen	2008-2009	MD/PhD. Student	residency
Kevin Quackenbush	2014-2015	M.D. Student	residency
Connor Hughes	2018-2022	MD/PhD Student	MD/PhD Student

TRAINEES AND FELLOWS

Name	Date	Prior Position	Current Position
Wen Wee Ma, MD	2006-2007	Oncology Fellow	Assistant Professor, Roswell Park Cancer Institute
Rajesh Kumar, PhD	2007	Post-Doc Fellow	Research Faculty, Johns Hopkins
Sujatha Nallapareddy (MD)	2007-2010	Oncology Fellow	Adjunct Faculty, University of Colorado School of Medicine
Arvind Dasari, MD	2009-2011	Oncology Fellow	Faculty, MD Anderson Cancer Center (GI Cancer)
Christopher Thompson, MD	2010-2012	Oncology Fellow	Medical Oncologist, OK
Ryan McWilliams, MD	2011-2013	GI fellow	Endoscopist, Ft. Collins
David Tai, MBBS	2013-present	Post-Doc Fellow	Faculty, Univ Singapore
Maria Jeppeson, MS	2014	Pre-Doc	Faculty, Copenhagen
Aaron Scott, MD	2014-2016	Chief Fellow	Faculty, Univ Arizona
Gentry King, MD	2016-present	Oncology Fellow	Faculty, Univ Washington

*Pia Morelli, MD/PhD (NCI)	2019-2020	NCI Oncology Fellow	Faculty MD Anderson
Rob Lentz, MD	2020-present	Oncology Fellow/T32	Faculty, AMC/Colorado
Ben Ueberroth	2024-present	Oncology Fellow	Oncology Fellow

*2019-2020 NCI Diversity Career Development Program (DCDP)- faculty mentor

JUNIOR FACULTY

Name	Date	Prior Position	Current Position
Stephen Leong, M.D.	2008-2016	Assistant Professor	Associate Professor
Antonio Jimeno, M.D., Ph.D.	2008-2016	Assistant Professor	Associate Professor
Colin Weekes, M.D., Ph.D.	2008-2016	Assistant Professor	Associate Professor
Karl Lewis, M.D.	2008-2015	Assistant Professor	Associate Professor
Chris Lieu, M.D.	2011-present	---	Assistant Professor
Erica Bradshaw Pierce, PhD	2012-2014	Post-Doctoral Fellow	Research Associate Dept of Pharmacology
Eun Kee Song, MBBS	2012-2013	Professor	Professor, Chonbuk Med Sch Joenju, South Korea
Dan LaBarbera, PhD	2012-2018	Assistant Professor	Assistant Professor, Dept of Pharmacology
Heather Leach, PhD	2016-present	Assistant Professor	Assistant Professor, CSU Health & Exercise Science
Lindsey Davis, MD	2016-present	Assistant Professor	Assistant Professor
Alexis Leal, MD	2017-present	Assistant Professor	Assistant Professor

RESEARCH GRANT SUPPORT – ACTIVE

Title: **P30CA046934-23S4**

Principal Investigator: Rich Schulick

Source: National Institute of Health

Dates: 2/2/2017 -1/31/2022

Percent Effort: 8%

Total Direct Costs: \$174,686

Purpose: This is the Cancer Center Support Grant (CCSG). I served as co-leader of the Developmental Therapeutics Program (one of 4 cancer center programs), which has >100 Members, from 2010-2018 (two renewal cycles). Responsibilities included co-writing the CCSG, planning retreats, reviewing Membership applications, and developing inter- and intra-programmatic collaborations. In 2017, I was promoted to **Associate Director (AD) for Translational Research**. In 2022, I was named **AD for Clinical Services** to compliment my CMO role.

Title: **2UM1CA186691**

Principal Investigator: Wells Messersmith (Colorado PI); M. Carducci (Johns Hopkins, Grant PI)

Source: National Institute of Health / NCI

Dates: 3/1/2020-2/28/2026

Percent Effort: 3%

Total Direct Costs: \$1,111,145

Purpose: The goal of this project is to support the “Johns Hopkins Translational Science Team and Consortium for ETCTN Studies,” one of six UM1 grants funded throughout the US and Canada to support cancer drug development and novel combinations in partnership with the NCI.

Title: **1 U10 CA 180834-01 Lead Academic Participating Sites (LAPS)**

Principle Investigator: A, Elias, MD

Source: NIH/NCI

Dates: 07/01/2020 – 06/30/2025

Role: Co-Investigator and Executive Steering Committee Member

Effort: 5%

Direct Costs: \$610,278/year

Aims/Goals: The goal of this project is to support the NCI designated cancer center efforts to foster and develop cooperative group and investigator initiated clinical trials at community affiliated and University of Colorado academic sites.

RESEARCH GRANT SUPPORT - **PRIOR FUNDING:**

Title: **Mentored Research Scholar Grant in Applied and Clinical Research**

Principal Investigator: Heather Leach, PhD (Mentor: Messersmith)

Source: American Cancer Society

Dates: 7/1/2018 – 6/30/2021 (NCE)

Total Direct Costs: \$725,000

Purpose: The goal of this project, “Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors” will examine factors associated with physical activity maintenance in colorectal cancer survivors.

Title: **1T32CA236734-01 Institutional National Research Service Award**

Principal Investigator: A Jimeno, MD/PhD (Mentor: Messersmith/Mentee: Robert Lenz, MD)

Source: NIH/NCI

Dates: 7/1/2020 – 6/30/2021

Total Direct Costs: \$167,443

Purpose: The goal of this project is to train future oncology clinical providers and researchers in the most advanced and promising forms of immune-directed and cell therapy. I serve as the primary mentor for Dr. Lentz, a fellow in my division.

Title: **K12CA086913 Paul Calabresi Award for Clinical Oncology Research Scholars**

Principal Investigator: S. Lindsey Davis, MD (Mentor: Messersmith)

Source: NIH/NCI

Dates: 10/1/2018 – 9/30/2021

Total Direct Costs: \$167,443

Purpose: The goal of this project is to identify biological and clinical predictors of immune-related adverse events associated with immune-oncology agents. I serve as the primary mentor for Dr. Davis, a junior faculty member in my division.

Stand Up to Cancer/Lustgarten Foundation

Principal Investigator: David Ryan, MD (Colorado PI: Messersmith)

Dates: 05/01/2018 – 04/30/2021

Effort: 5%

Total Direct Costs: \$2,600,000

Title: A Randomized Phase 2 Study of Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Aims/Goals: The goal of this project is to develop novel therapies for localized pancreatic cancer. This is part of the “pancreatic cancer collective.”

Title: **W81XWH-15-1-0173 (CA140772)**

Source: Department of Defense IDEA Award: Targeting the ALDH+ Tumorigenic Population in Colorectal Cancer

Principal Investigator: Messersmith

Dates: 7/1/2015 – 12/31/2020 (NCE)

Percent Effort: 5%

Total Direct Costs: \$ 226,239

Purpose: The goal of this project is to develop therapies targeting tumor-initiating cells in colorectal cancer.

Title: **Colorado Office of Economic Development and International Trade**

Principal Investigator: Wells Messersmith

Source: State of Colorado

Dates: 12/15/2016-12/14/2019

Total Direct Costs: \$500,000

Purpose: The goal of this project is to support biomarker identification and pre-clinical development of candidate compounds and immunotherapeutics in Colorado; provide commercialization management; and provide support for IIT's.

Title: **1U01AA021724-01A1**

Principal Investigator: Vasilis Vasiliou

Source: National Institute of Health / NIAAA

Dates: 9/25/2014-8/31/2019

Percent Effort: 3%

Total Direct Costs: \$439,182

Purpose: The goal of this project is to understand the role of mitochondrial aldehyde dehydrogenase 1B1 (ALDH1B1) in ethanol- induced colorectal carcinogenesis.

National Institutes of Health/National Cancer Institute

Title: **1 R01 CA152303-01: Biomarker-driven Src Studies in Colorectal Cancer**

Principal Investigator: Messersmith

Source: National Cancer Institute

Dates: 07/01/2010 to 06/30/2016

Percent Effort: 10%

Total Direct Costs: \$1,250,000

Purpose: The goal of this study is to complete preclinical work on a biomarker identifying Src sensitive colorectal tumors, and then translate these findings into the clinic in a phase II clinical

Title: **Lustgarten Cancer Foundation**

Principal Investigator: Wells Messersmith

Dates: 1/1/2012 to 12/31/2013

Percent Effort: 10%

Total Direct Costs: \$92,000

Purpose: this grant supports correlative science associated with a phase II study of a gamma secretase inhibitor (notch pathway) in pancreas cancer.

Title: **“IndiTreat - Individualized treatment of colorectal cancer patients”**

Principal Investigator: Ole Thustrup, PhD; Technical University of Denmark, DTU Nanotech (USA PI: Messersmith)

Source: European Union / Danish Government

Dates: 7/1/2013-6/30/2015

Percent Effort: 3%

Total Direct Costs: 1,043,000 Dutch Kroner

Purpose: I serve as key personnel/US PI on this project to develop a nanoscale technology whereby tumor cells will be screened for sensitivity to hundreds of compounds on a single chip. This project is an international collaboration between the Technical University of Denmark, The School of Electronics and Computer Science (Univ. Southampton, UK), and the University of Colorado (Messersmith).

Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP)
Title: **CA120261** - "Novel Antimetastatic Agents for the Treatment of Drug-Resistant and Metastatic Colon Cancer"

Principal Investigator: Dan LaBarbera, PhD (mentor: Messersmith)

Dates: 6/1/13-5/31/15

Total Direct Costs: \$240,000 (Indirect Costs: \$137,101)

Percent Effort: 0%

Purpose: I served as the mentor for this career development award. The goals of this project is to develop a novel class of topoisomerase II α inhibitors, which are effective against the metastatic phenotype in colorectal cancers and overcome mechanisms of drug resistance observed with current clinically used topoisomerase II α drugs.

Title: **Academic Gastrointestinal Cancer Consortium (AGICC)**

Principal Investigator: Wells Messersmith

Dates: 9/1/2008 to 8/31/2012

Percent Effort: 10%

Total Direct Costs: \$125,000

Purpose: this grant supports clinical/translational research in gastrointestinal oncology with a consortium of academic institutions including University of Colorado, University of North Carolina, Vanderbilt, Fox-Chase, and others.

National Institutes for Health/National Cancer Institute

Title: **National Cancer Institute Clinical Investigator Team Leadership Award**

Source: National Institutes of Health / American Society of Clinical Oncology

Dates: 10/01/2009 to 09/31/2011

Percent Effort: not applicable

Total Direct Costs: \$100,000

Purpose: The purpose of this grant is to support leaders in clinical investigation and translational science.

Title: **K23CA115500**: Evaluation of Oral EGFR Inhibitors in Colorectal Cancer

Principal Investigator: Wells Messersmith

Source: National Cancer Institute

Dates: 09/01/2005 to 08/30/2010

Percent Effort: 75%

Total Direct Costs: \$700,650

Purpose: The purpose of this study is to investigate the clinical activity and biologic effects of oral Epidermal Growth Factor Receptor tyrosine kinase inhibitors in colorectal cancer, and to develop a specific expertise in validated, quantitative pharmacodynamic assays for cell signaling inhibitor drug development.

Title: **R21CA117125**: Evaluation of BAY43-9006/Cetuximab in Colorectal Cancer

Principal Investigator: Wells Messersmith

Source: National Cancer Institute

Dates: 07/01/2006 to 06/30/2008 (no cost extension)

Percent Effort: 5%

Total Direct Costs: \$500,000

Purpose: The goal of this study is to complete a phase I/II Clinical Trial, pharmacological, biological study of BAY 43-9006 in combination with cetuximab and irinotecan in patients with advanced colorectal cancer.

Title: **R21CA135622**: Evaluation of Src Inhibitors in Pancreas Cancer

Principal Investigator: Wells Messersmith

Source: National Cancer Institute

Dates: 10/01/2008 to 12/30/2011 (no-cost extension)

Percent Effort: 10%

Total Direct Costs: \$500,000

Purpose: The goal of this study is to complete a Cancer Therapy Evaluation Program -supported phase II clinical trial of AZD0530, an oral Src inhibitor, in previously treated patients with metastatic pancreas cancer and to evaluate drug effects on tumor tissue in a subset of patients. The trial is being conducted by the University of Colorado Cancer Center and the Phase II Consortium, an National Cancer Institute-contracted cooperative group anchored at the Mayo Clinic.

Title: National Institutes of Health **Loan Repayment Program**

Source: National Institutes of Health

Dates: 07/01/2004 to 06/30/2008

Percent Effort: not applicable

Total Direct Costs: \$85,000

Purpose: The purpose of this grant is to support researchers who wish to stay in academics despite large educational debts.

OTHER

NATIONAL COMPREHENSIVE CANCER NETWORK CLINICAL TRIALS NETWORK

Title: Thymidylate Synthase Genotype Directed Phase II Trial of Capecitabine for Advanced Pancreas Cancer

Principal Investigator: Wells Messersmith

Source: NCCN Clinical Trials Network

Dates: 07/01/2005 to 01/01/2008

Percent Effort: 5%

Total Direct Costs: \$260,000

Purpose: This trial incorporates genetic testing for a gene polymorphism (TSER) and treats only patients with a specific polymorphism to increase response rates to capecitabine.

MARYLAND CIGARETTE RESTITUTION FUND

Title: Evaluation of Src Inhibitors in Pancreas Cancer

Principal Investigator: Wells Messersmith

Source: Maryland Cigarette

Dates: 01/01/2007 to 12/31/2007

Percent Effort: 5%

Total Direct Costs: \$35,000

Purpose: The purpose of this project is to characterize the pharmacodynamic effects of Src inhibitors on pancreas cancer tissue using a xenograft model.

AMERICAN SOCIETY OF CLINICAL ONCOLOGY YOUNG INVESTIGATOR AWARD

Title: Pharmacogenetic Study of Gefitinib

Principal Investigator: Wells Messersmith

Source: American Society of Clinical Oncology

Dates: 07/01/2004 to 06/30/2005

Percent Effort: 25%

Total Direct Costs: \$35,000

Purpose: The purpose of this grant was to support young academic investigators in cancer research projects.

PASSANO CLINICIAN SCIENTIST AWARD

Title: Evaluation of Oral EGFR Inhibitors in Colorectal Cancer

Principal Investigator: Wells Messersmith

Source: Johns Hopkins University

Dates: 01/01/2005 to 01/01/2006

Percent Effort: (overlap with K23)

Total Direct Costs: \$32,500

Purpose: This grant/award provided support to young investigators prior to obtaining their first career development award. The project was the same as the submitted K23, and funding ended when the K23 was awarded.

AMGEN ONCOLOGY INSTITUTE CAREER DEVELOPMENT AWARD

Title: Pharmacodynamic Evaluation of Gefitinib in Previously Untreated Resectable Rectal Cancer Patients

Principal Investigator: Wells Messersmith

Source: Amgen Oncology Institute

Dates: 07/01/2004 to 06/30/2007

Percent Effort: 10%

Total Direct Costs: \$180,000

Purpose: The purpose of this grant was to determine the pharmacodynamic effects of gefitinib on tumor and normal tissues on EGFR signaling pathways, as well as to develop the career of a young investigator.

RESEARCH INTERESTS AND EXPERTISE:

Clinical Trials (served as PI of 85 trials; 24 [first-in-human](#) studies)

1. Principal Investigator, COMIRB 24-2609 "A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients with Locally Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers" (supported by Accent Therapeutics; [first in human](#))
2. Principal Investigator, COMIRB 24-1423 "C5421001: A Phase 1 Open-Label Master Protocol Testing PF-07934040 As A Single-Agent And In Combination With Other Targeted Agents In Participants With Advanced Solid Tumors Harboring Mutations In The KRAS Gene" (supported by Pfizer; [first in human](#))
3. Principal Investigator, COMIRB 24-1326, "A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors: RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma; RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma; RMC-

- 6236 in Combination with Gemcitabine and Nabpaclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (supported by Revolution Medicines)
4. Principal Investigator, COMIRB 23-1337, "NX-1607-101: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-C) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types" (supported by Nurix; [first in human](#))
 5. Principal Investigator, COMIRB 22-2362, "C-800-25: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer without Liver Metastases" (supported by Agenus)
 6. Principal Investigator, COMIRB 21-5119, "CBP 21-01: Multicenter, randomized, parallel group, phase 2 study to establish the efficacy and safety of combinations of CBP501, cisplatin, and nivolumab for ≥3rd line treatment of patients with exocrine pancreatic cancer" (supported by CanBas, Co)
 7. Principal Investigator, COMIRB 21-4178, "A Phase I, Open-Label, Multicenter Study of FT538 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors" (Supported by Fate Therapeutics)
 8. Principal Investigator, COMIRB 20-3038, "A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients with Advanced Solid Tumor Malignancies" (Supported by Racal Therapeutics; [first in human](#))
 9. Principal Investigator, COMIRB 20-2976, "A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors" (supported by PureTech; [first in human](#))
 10. Principal Investigator, COMIRB 21-2951, "A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy" (Supported by Mirati)
 11. Principal Investigator, COMIRB 19-2761, "A Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07062119 in Patients with Advanced Gastrointestinal Tumors" (Supported by Pfizer; [first in human](#))
 12. Principal Investigator, COMIRB 19-1302, "Dose Escalation and Basket Expansion Study of GB1275 Monotherapy and in Combination with Anti-PD-1" (Supported by Gossamer Biotech; [first in human](#))
 13. Principal Investigator, COMIRB 19-1458, "Phase 1a/b Dose-Escalation and Dose Expansion Study of NGM120 in Subjects With Advanced Solid Tumors " (Supported by NGM Pharmaceuticals; [first in human](#))
 14. Principal Investigator, COMIRB 19-0232, "Phase 1 clinical trial of TR1801-ADC in patients with select solid tumors expressing c-Met " (Supported by Tanabe; [first in human](#))
 15. Principal Investigator, COMIRB 18-1263, "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumor" (Supported by Beigene)
 16. Principal Investigator, COMIRB 18-0871, "A Phase Ib/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma" (Supported by AstraZeneca)

17. Principal Investigator, COMIRB 18-1347, "Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer" (Supported by Stand Up to Cancer Grant to MGH)
18. Principal Investigator, COMIRB 18-2436, "Predictors of physical activity maintenance in colorectal cancer survivors" (Supported by the American Cancer Society CDA to Heather Leach, PhD)
19. Principal Investigator, COMIRB 18-0965, "A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors " (Supported by Pfizer)
20. Principal Investigator, COMIRB 18-0021, "An open-label, single-arm, two-stage phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer" (IND held by Messersmith/Criterium; supported by Exelixis)
21. Principal Investigator, COMIRB 17-1154, "A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors " (Supported by OncoMed; [first in human](#))
22. Principal Investigator, COMIRB 17-1452, "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas" (Supported by Aduro; [first in human](#))
23. Principal Investigator, COMIRB 17-1020, "A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults with Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas" (supported by Arduro)
24. Principal Investigator, COMIRB 16-2248, "A Phase I Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma" (Supported by Alexo Therapeutics; [first in human](#))
25. Principal Investigator, COMIRB 16-1332, "A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment and Efficacy of INCB Combinations in Advanced Solid Tumors" (Supported by Incyte)
26. Principal Investigator, COMIRB 16-0599, "A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination with the anti-PD-L1 Antibody, Durvalumab (MEDI4736) and IPH2201 in Advanced Refractory Solid Tumors" (Supported by Lilly)
27. Principal Investigator, COMIRB 16-0546, "A randomized phase II study of durvalumab (MEDI4736), an anti-PD-L1 antibody, as an adjuvant therapy compared to observation alone in patients with borderline resectable pancreatic ductal adenocarcinoma following neoadjuvant therapy and successful surgical resection" (IIT, I hold the IND; supported in part by AstraZeneca)
28. Principal Investigator, COMIRB, "Expanded Access, Physician-Sponsored Trial - for PF 03084014 in Patients with Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit" (IIT, I held the IND)
29. Principal Investigator, COMIRB 15-1354, "D3-002 A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumors" (Sponsored by D3 Pharma/Singapore Government; [first in human](#))
30. Principal Investigator, COMIRB 15-0984, "Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)" (Sponsor: NCI/CTEP)
31. Principal Investigator, COMIRB 15-0150, "Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates" (sponsor: Celgene; Academic GI Cancer Consortium)
32. Principal Investigator, COMIRB 15-2076, "An Open-Label Phase IB Study of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Abraxane (Nab-Paclitaxel) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma" (supported by Pfizer)

33. Principal Investigator, COMIRB 14-1305, “MLN0264 A Phase 2 Trial of MLN0264 in Previously Treated Patients with Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)” (supported by Millenium/Takeda; [first in human](#))
34. Principal Investigator, COMIRB 14-1306, “MLN0264 A Phase 2 Trial of MLN0264 in Previously Treated Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)” (supported by Millenium/Takeda; [first in human](#))
35. Principal Investigator, COMIRB 13-2592, “IMMU-132-01: A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer” (supported by Immunomedics)
36. National Chair and Local Principal Investigator, COMIRB 14-0762, “Phase 1b/2 Study of PF-03084014 + Gemcitabine and nab-Paclitaxel in Patients with Metastatic Ductal Adenocarcinoma of the Pancreas” (supported by Pfizer)
37. Principal Investigator, COMIRB 14-0581, “A Phase 1, Dose Escalation Study of PF-06664178 in Patients With Locally Advanced or Metastatic Tumors” (supported by Pfizer; [first in human](#))
38. Principal Investigator, COMIRB pending, “A Phase 1b Dose Escalation Study of OMP-518R5 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer”
39. Principal Investigator, COMIRB pending, “A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer”
40. Principal Investigator, COMIRB pending, “PROTOCOL GO28074: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER”
41. National Chair and Local Principal Investigator, COMIRB pending, “A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer” (supported by Onconova)
42. Principal Investigator, COMIRB pending, “An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C” (supported by Millenium; [first in human](#))
43. Principal Investigator, COMIRB “A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors” (supported by Pfizer; first in human)
44. Principal Investigator, COMIRB pending, “Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patient with Advanced HCC” (supported by Southwestern Oncology Group)
45. Principal Investigator, COMIRB 11-0345 (University of Colorado School of Medicine), “MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors and Leukemia” (supported by GlaxoSmithKline)
46. Principal Investigator, COMIRB 11-0017, “S0713, A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer” (supported by Southwestern Oncology Group)
47. Principal Investigator, COMIRB 11-0068, “A Phase I Study to Evaluate the safety, pharmacokinetics, and pharmacodynamics PF-04449913, an Oral Hedgehog Inhibitor, Administered as a Single Agent in Select Solid Tumors” (supported by Pfizer; [first in human](#))

48. Principal Investigator, COMIRB 10-0923 (University of Colorado School of Medicine), “A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients with Locally Advanced or Metastatic Epithelial Tumors” (supported by Genentech; [first in human](#))
49. Principal Investigator, COMIRB 10-0590 (University of Colorado School of Medicine), “A Phase 1b/2 Study Evaluating IPI-926 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer” (supported by Infinity)
50. Principal Investigator (National and Local), COMIRB 10-0273, “A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer” (supported by institutional funds)
51. Principal Investigator, COMIRB 09-0508 (University of Colorado School of Medicine), “Evaluation of Clinical Parameters as Prognostic Factors in Cancer Patients Participating in Phase I Clinical Trials” (supported by institutional funds)
52. Principal Investigator, COMIRB 09-0369 (University of Colorado School of Medicine), “A Phase Ib study of the safety and pharmacokinetics of APO2L/TRAIL administered in combination with the FOLFOX regimen and Bevacizumab in patients with previously untreated locally advanced, recurrent, or metastatic colorectal cancer” (supported by Genentech)
53. Principal Investigator, COMIRB 09-0228 (University of Colorado School of Medicine), “A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP inhibitor, Olaparib, Alone in Previously-Treated Patients with Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status” (supported by AstraZeneca and the Aptium Gastrointestinal Cancer Consortium)
54. Principal Investigator, COMIRB 09-0250 (University of Colorado School of Medicine), “Pilot Study of Cognitive Impairment in Cancer Patients Following Chemotherapy” (supported by institutional grant on Aging and Cancer)
55. Principal Investigator, COMIRB 09-0166 (University of Colorado School of Medicine), “A phase I trial of PF-03084014 in patients with advanced solid tumor malignancy and t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma” (supported by Pfizer; [first-in-human](#))
56. Principal Investigator, COMIRB 08-0645 (University of Colorado School of Medicine), “Evaluation of KRAS testing methods in colorectal cancer” (supported by institutional funds)
57. Principal Investigator, COMIRB 08-0635 (University of Colorado School of Medicine), “E5204, Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin vs oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab for patients with state II or III rectal cancer receiving preoperative chemoradation” (supported by Southwestern Oncology Group)
58. Principal Investigator, COMIRB 08-0439 (University of Colorado School of Medicine), “Gastrointestinal cancer tissue collection for animal xenograft studies” (supported by institutional funds)
59. Principal Investigator, COMIRB 08-0395 (University of Colorado School of Medicine), “Open label multiple dose escalation study to investigate the safety, pharmacokinetics and pharmacodynamics of the MEK inhibitor GSK 1120212 in subjects with solid tumors or lymphoma” (supported by GlaxoSmithKline; [first-in-human](#))
60. Principal Investigator, COMIRB 07-1192 (University of Colorado School of Medicine), “MC0547 - A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer” (supported by Cancer Therapy Evaluation Program and R21)
61. Principal Investigator, COMIRB 07-0571 (University of Colorado School of Medicine), “Phase I/II clinical, pharmacological, and biological study of BAY43-9006 in

- combination with cetuximab and irinotecan in patients with advanced colorectal cancer” (2007-2010, supported by R21 and K23)
62. Principal Investigator, COMIRB 07-0855 (University of Colorado School of Medicine), “N0147: Randomized Phase III trial of Oxaliplatin (OXAL) plus 5 Fluorouracil (5-FU) / Leucovorin (CF) with or without Cetuximab (C225) after curative resection for patients with stage III colon cancer” (supported by Southwestern Oncology Group)
 63. Principal Investigator, COMIRB 07-1193 (University of Colorado School of Medicine), “Randomized phase 2B study of sunitinib plus oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) vs bevacizumab plus FOLFOX as first line treatment in patients with metastatic colorectal cancer” (supported by Pfizer)
 64. Principal Investigator, COMIRB 06-0703 (University of Colorado School of Medicine), “NSABP R-04 A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum” (supported by Southwestern Oncology Group)
 65. Principal Investigator, N021321 (University of Colorado), “Phase I Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients with Refractory Metastatic or Locally Advanced Solid Tumors” (supported by Roche; [first-in-human](#))
 66. Principal Investigator, ENMD-2076 CL 001 (University of Colorado School of Medicine), “An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients with Advanced Cancer” (supported by Entremed; [first-in-human](#))
 67. Principal Investigator, COMIRB 06-0445 (University of Colorado School of Medicine), “Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates” (Southwestern Oncology Group S0425)
 68. Principal Investigator, COMIRB 05-1014 (University of Colorado School of Medicine), “A Randomized Phase III Study Comparing 5-FU, LV, and Oxaliplatin vs. 5-FU, LV, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer At High Risk For Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers” (Southwestern Oncology Group E5202)
 69. Principal Investigator, COMIRB 04-1135 (University of Colorado School of Medicine), “Oxaliplatin Plus Protracted Infusion 5-FU and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates” (Southwestern Oncology Group 0356)
 70. Principal Investigator, COMIRB 05-0941 (University of Colorado School of Medicine), “Southwestern Oncology Group C80405 A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum” (supported by Southwestern Oncology Group)
 71. Principal Investigator, J0220 (Johns Hopkins), “A Phase I, Pharmacological and Biological Study of OSI-774 in Combination with FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) in Patients with Advanced Colorectal Cancer” (2003 – 2007, K23 supported)
 72. Principal Investigator, J0359 (Johns Hopkins), “A Phase I/II Study of ABT-751 in Combination with XELIRI (Capecitabine and Irinotecan) in Patients with Advanced Colorectal Cancer” (2004 – 2007, supported by the Goodwin Foundation)

73. Principal Investigator, J0450 (Johns Hopkins), "Phase 1 Dose-Escalation Study of Oral SKI-606 in Subjects with Advanced Malignant Solid Tumors" (2005-2006, support by Wyeth Pharmaceuticals; [first-in-human](#))
74. Principal Investigator, J0560 (Johns Hopkins), "Thymidylate Synthase Genotype Directed Phase II Trial of Capecitabine for Advanced Pancreas Cancer" (2005 – 2007, supported by National Comprehensive Cancer Network)
75. Principal Investigator, J04104 (Johns Hopkins), "Phase I/II clinical, pharmacological, and biological study of BAY43-9006 in combination with cetuximab and irinotecan in patients with advanced colorectal cancer" (2005 – present, supported by R21 and K23)
76. Principal Investigator, J0596 (Johns Hopkins), "Randomized study of XELOX q3W and bevacizumab versus XELOX q2W and bevacizumab as first-line treatment for patients with metastatic colorectal cancer" (2007, supported by Roche)
77. Principal Investigator, J0633 (Johns Hopkins), "Phase II Study of Bevacizumab plus Erlotinib in Patients with Advanced Hepatocellular Cancer (HCC)" (2006, supported by the Phase II Consortium)
78. Principal Investigator, ECOG 5202 (Johns Hopkins), "Randomized Phase III Study Comparing FOLFOX versus FOLFOX/Avastin in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers" (2006-2007, supported by Eastern Cooperative Oncology Group)
79. Protocol Chair, MC044I (Johns Hopkins), "Phase II Study of AZD0530 in Previously Treated Patients with Pancreas Cancer" (2007-present, supported by Phase II Consortium)
80. Principal Investigator, ARQ501-212 (Johns Hopkins), "A Phase II Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naïve, Unresectable Pancreatic Adenocarcinoma" (2006, supported by ArQule, Inc)
81. Principal Investigator, Gastrointestinal-0470-01 (Johns Hopkins), "Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients with Solid Malignancies" (2007, supported by SuperGen, Inc, [first in human](#))
82. Principal Investigator, CC-4047-PANC-001 (Johns Hopkins), "A Phase I/II Study of CC-4047 in Combination with Gemcitabine in Subjects with Untreated Advanced Carcinoma of the Pancreas" (2007, supported by the Pancreas Cancer Research Team)
83. Co-Principal Investigator, J0072 (Johns Hopkins), "Phase I Study of Continuous Weekly Dosing of Dimethyl Benzoylphenylurea (BPU) in Patients with Solid Tumors Not Responding to Conventional Therapy" (2003-2005, supported by U01, [first in human](#))
84. Principal Investigator, J0246 (Johns Hopkins), "A Phase I Study to Determine the Maximum Tolerated Dose of ET-743 Administered in Combination with Gemcitabine to Subjects with Advanced Malignancies" (2003-2005, supported by Johnson and Johnson PRD)
85. Principal Investigator, "A Randomized, Open-Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract" (2005, supported by OSI Pharmaceuticals)

FDA IND's Held

1. "Expanded Access, Physician-Sponsored Trial - for PF 03084014 in Patients with Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit" (COMIRB 15-2088, IND 129267)

2. “A randomized phase II study of durvalumab (MEDI4736), an anti-PD-L1 antibody, as an adjuvant therapy compared to observation alone in patients with borderline resectable pancreatic ductal adenocarcinoma following neoadjuvant therapy and successful surgical resection” (COMIRB 16-0546, IND 132631)

Laboratory-Based Studies

1. Principal Investigator, COMIRB 15-2341, “Targeting the ALDH+ Tumorigenic Population in a Colorectal Cancer Patient-Derived Tumor Xenograft Model”
2. Principal Investigator, COMIRB 11-1188 “Molecular Analysis of Desmoid Tumors”
3. Principal Investigator, COMIRB 08-0645, “Evaluation of KRAS Testing Methods in Colorectal Cancer”
4. Principal Investigator, COMIRB 08-0439, “Gastrointestinal Cancer Tissue Collection Studies for Animal Xenograft Studies”

Animal Protocols

1. Principal Investigator, #91410(05)1E, “Development of a Rationale Combination Therapies for Colorectal and Pancreatic Cancer”
2. Co-Investigator, 96813(04)1E: Development of Novel Anticancer Drugs for Colorectal and Pancreatic Cancers
3. Co-Investigator, 96815(01)1E: Therapeutic approaches for the treatment of colon and pancreatic cancer in orthotopic and metastatic models.
4. Co-Investigator, 96815(05)1E: Targeting the WNT and Notch pathways in Colorectal Cancer
5. Co-Investigator, 96815(07)1C: Evaluation of MET pathway inhibitors in CRC and pancreatic cancer explants in a human HGF knockin mouse model.

SELECTED INVITED ORAL/POSTER PRESENTATIONS AND ABSTRACTS:
(available upon request)

SEMINARS AND TALKS GIVEN:

June 2025	Colorectal Cancer Conference (Virtual) “Metastatic CRC: Personalizing Patient Care Using Current Evidence and Innovative Therapeutic Strategies”
April 2025	Annual Rocky Mountain Pancreas Symposium (Aurora, CO) “The Role of Neoadjuvant Approach in Pancreatic Cancer” Moderator, Speaker, Session II
January 2025	42 nd Annual Medical/Surgical Gastroenterology (Beaver Creek, CO) “Pancreatic Multi-Disciplinary Clinic: Seven Cases”
January 2025	GI Symposium (ASCO/AGA/SSO) (San Francisco, CA) Discussant, Oral Abstract Session “Optimizing Targeted Drugs and Immunotherapy”
November 2024	Gail Jackson Memorial Award (Baltimore, MD) “To Johns Hopkins, with Gratitude”
June 2024	ASCO Annual Meeting (Chicago, IL) Chair, Division Chiefs and Department Chairs Meeting
April 2024	Binaytara Foundation Heme/Onc Conference (Denver, CO) Keynote Lecture: “Precision Medicine in GI Cancers”
November 2023	Virginia Oncology Associates (VA Beach, VA) 24 th Annual Oncology Educational Conference “New Developments in Colorectal Cancer”
June 2023	ASCO Annual Meeting (Chicago, IL)

April 2023	Discussant, Developmental Therapeutic Poster Session "Small Molecules: Ready for the Big Game?" Research to Practice/Year in Review (virtual) "Colorectal Cancer"
November 2022	World Pancreatic Cancer Day (Umea, Sweden) Norrlands Universitetssjukhus / Umeå University (virtual) "Oncologic Treatment of Locally Advanced Pancreatic Cancer"
October 2022	ResearchToPractice/Florida Cancer Specialists (Orlando, FL) Clinical Implications of Key Recent Data Sets in Oncology "Gastrointestinal Cancers"
September 2022	Master Lecture Series, MedPro, Evolving Oncology Therapy (Denver, CO) "Early-Stage Colon Cancer"
April 2022	UCHealth/Chancellor's Benefactor Recognition Event (Denver, CO) Moderator, Panel Discussion on novel therapies and trials
February 2022	National Pancreas Foundation (virtual) Meeting Pancreatic Cancer Webinar: A Multidisciplinary Approach
February 2022	North and South Carolina Oncology Association (virtual and in-person) Research to Practice/Recent Advances in Medical Oncology "GI Cancers: Gastric, Biliary, HCC, Colorectal, and Pancreatic Cancer"
September 2021	APP Oncology Summit (Denver, CO) "Improving Outcomes in BRAF-Mutant mCRC Through Screening and Targeted Therapy"
August 2021	Meet The Professor: Management of Gastrointestinal Cancer ResearchToPractice (virtual)
June 2021	ASCO Annual Meeting (virtual) Oncology Division Chiefs and Department Chairs Session Role: co-Leader, Panelist, and Discussion Leader
May 2021	Medical Oncology Association Of Southern California Series Current Concepts and Recent Advances in Oncology "GI Cancers: colorectal, gastroesophageal, hepatocellular"
May 2021	NCCN Oncology Tumor Board (Webinar) "Advances in the Treatment of Metastatic Colon Cancer"
April 2021	Virtual Scientific Workshop (OnLive.com) "Treatment Strategies in HER2+ Gastrointestinal Malignancies"
April 2021	Massachusetts General Hospital Cancer Center (Boston, MA) Cancer Center Grand Rounds Debate: "Radiation Therapy for Locally Advanced Pancreatic Cancer"
March 2021	6 th Annual School of Gastrointestinal Oncology (SOGO) Lecture: "Novel Agents for GI Cancers" Debate: "Adjuvant Therapy after Liver Metastectomy: Yes"
January 2021	Physicians Education Resource (Webinar Program) "GI Oncology Expert Tumor Board: Leveraging Immune Biomarkers"
November 2020	Research to Practice "Beyond the Guidelines: Biomarker Assessment and Targeted Therapy for Metastatic Colorectal Cancer" (Video Program due to COVID)
May 2020	Oncology Nursing Society Annual Meeting (Virtual) Research To Practice Webinar "Management of Gastrointestinal Cancers"
May 2020	Rescheduled: NCCN Tumor Board Series Webinar "Multi-Disciplinary Management of Rectal Cancer"
February 2020	UC-AMC "Transforming Healthcare" series (Aurora, CO)

January 2020	“Immunotherapy for Colorectal Cancer” and “Case Discussion” CME Symposium, Immunotherapy in GI Cancer (San Francisco, CA) “State of the Science of Immunotherapy in Lower GI Malignancies: Evaluating the Relevant Biomarker Alignments and Translating Latest Data in Colorectal”
December 2019	Grand Rounds, Jefferson Cancer Center (Philadelphia, PA) “Colorectal Cancer”
November 2019	Chemotherapy Foundation Symposium (New York, NY) “MSI-High/Tumor Mutational Burden”
October 2019	Grand Rounds, Department of Medicine (Aurora, CO) University of Colorado School of Medicine “Colorectal Cancer: Present and Future”
September 2019	LSU Oncology Grand Rounds (New Orleans, LA) “Update in GI Cancers” (Research to Practice)
June 2019	ASCO Annual Meeting (Chicago, IL) Discussant, Plenary Session, “POLO Trial” Panelist, Post-Plenary Session Faculty, Grant Writing Workshop Organizer/Speaker, ASCO Division Chief’s Session Speaker/Leader, Biomarker Committee, Colon Task Force
May 2019	“State of the Science Summit (Denver Tech Center, CO) Chair and Lecturer, GI Malignancies “Metastatic Colorectal Cancer: Newly Diagnosed”
April 2019	“School of Gastrointestinal Oncology” (Washington, DC) Track Leader: “Case Discussions with the Experts” Lecturer, “Adjuvant Therapy for Stage IV Colorectal Cancer” Lecturer, “Handling Rare Molecular Subtypes in GI Cancers”
April 2019	Grand Rounds, Department of Surgery, University at Buffalo (Buffalo, NY) “Multi-Disciplinary Management of Colorectal Cancer” “Case Presentations” (surgery residents)
March 2019	NCCN Annual Meeting (Orlando, FL) “Management of Advanced Colorectal Cancer”
January 2019	Research to Practice, “Meet The Professor” session (San Francisco, CA) “Emerging Research in Gastrointestinal Cancers”
November 2018	Research to Practice (Santa Monica, CA) “Updates in Gastrointestinal Cancers”
October 2018	Research to Practice (Jersey City, NJ) “Updates in Gastrointestinal Cancers”
August 2018	“Best of ASCO” (Chicago, IL) “Discussion of Top 4 abstracts for ASCO 2018”
June 2018	OnLive Peer Exchange (Chicago, IL) Expert Perspectives on Colorectal Cancer (panelist)
June 2018	ASCO Post Video Interview (Chicago, IL) Updates in Colorectal Cancer 2018
May 2018	Transforming Health Care Lecture (Aurora, CO) “Immune Modulation for Cancer Therapeutics”
February 2018	Rocky Mountain Interventional Endoscopy Course (Aurora, CO) “The Role of Chemotherapy in Colorectal Cancer”
February 2018	Cedars-Sinai, Targeted Therapies for GI Cancers (Los Angeles, CA) “Targeted Therapies for Colorectal Cancer”
January 2018	Webinar, Postgraduate Institute for Medicine (PIM) (San Francisco, CA)

	“Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management”
January 2018	Case-Based Peer Perspectives: Colorectal Cancer (San Francisco, CA)
November 2017	Chemotherapy Foundation Symposium (New York, NY) “Practical Issues in Testing for Microsatellite Instability in GI Cancers”
November 2017	Webinar, National Comprehensive Cancer Network (NCCN) “Management of Colorectal Cancer”
October 2017	University of Tennessee West Oncology Conference (Memphis TN) “First-line treatment of Colorectal Cancer, and Novel Therapies”
June 2017	ASCO Annual Meeting (Chicago, IL) Discussant, Clinical Science Symposium, “Making Sense of CMS” Reviewer and Discussion Leader, Mock Grant Review Moderator, CME Program, “Update on Management of MSI-H Cancers”
May 2017	American Radium Society Annual Meeting (Colorado Springs, CO) “Adjuvant Therapy for Pancreas Cancer”
May 2017	Oncology Nursing Society Annual Meeting (Denver, CO) “Research to Practice Satellite Symposium”
March 2017	Faculty Panelist, Gastrointestinal Cancers NCCN 22 nd Annual Conference (Orlando, FL) “Systemic Management of Colorectal Cancer”
March 2017	ASCO Multi-Disciplinary Course (Marrakesh, Morocco) “Adjuvant Treatment of Colon Cancer” “Multi-disciplinary Management of Rectal Cancer” “Chemotherapy Toxicity Management” “Treatment of Metastatic Disease” “Multi-disciplinary Management of Anal Cancer”
February 2017	University of Colorado (Aurora, CO) Pathology Grand Rounds “Update in the Management of Colorectal Cancer”
September 2016	Wyoming Medical Center (Casper, WY) Medicine/Oncology Grand Rounds “Current Trends and Future Directions in Advanced Esophagogastric Cancers”
September 2016	Rocky Mountain Advanced Practice Provider Annual Meeting (Denver Tech Center, CO) “Targeted Therapies”
September 2016	AACR Conference “Colon Cancer: From Initiation to Outcomes” Speaker, Plenary Session 7: New Therapeutic Approaches (Tampa, FL) “Therapies Directed at the Wnt Pathway”
August 2016	NCCN Colorectal Cancer National Guideline Committee (Philadelphia, PA) Presenter, “Targeting HER2 in Colorectal Cancer”
July 2016	Speaker, “Best of ASCO” national meeting (Washington, DC) “Update on Colorectal Cancer: ASCO 2016 Annual Meeting”
June 2016	Visiting Professor, Cleveland Clinic Cancer Center (Cleveland, OH) Medicine Grand Rounds: “Update in Treating Colorectal Cancer” Oncology Grand Rounds: “Biomarker-Driven Trials in GI Cancers” Intern/Resident Conference: “Challenging GI Cancer Cases” Oncology Fellows’ Conference: “Value in Cancer Care”
June 2016	ASCO Annual Meeting (Chicago, IL) Chair, Poster Discussion Session, GI-Colorectal Cancer Roundtable Discussion Leader, Grant Writing Workshop

	Speaker, ASCO/European Cancer Organization (ECCO) "Value-Based Care: Colorectal Cancer"
June 2015	Webinar, CancerNet (Chicago, IL) "Overview of RAS mutations in 2 nd Line Colorectal Cancer"
May 2016	International Thyroid Oncology Group Meeting (Aurora, CO) "Biomarker-Driven Trials in Colorectal Cancer"
April 2016	School of Gastrointestinal Oncology (New York, NY) "State of the Art frontline strategies for colorectal cancer" "Beyond progression in relapsed colorectal cancer" "Phase I pipeline to GI cancers"
April 2016	1R25CA160013, Promoting Healthy Cancer Survivorship in Rural Colorado Primary Health Care Practices. iSurvive Webinar "Colon Cancer: Surveillance and Survivorship"
March 2016	Oncology Fellows' Conference (Aurora, CO) "Colorectal Cancer: 2016"
February 2016	Presenter, Oncology M&M (Aurora, CO) "Tumor Tissue for Research"
January 2016	ASCO/AGA/SSO GI Symposium (San Francisco, CA) Discussant, Oral Abstract Session "MAVERICC and STEAM trials"
December 2015	Roundtable (New York, NY) Cancer Research Institute/Fightcolorectalcancer "Immunotherapy for Colorectal Cancer: Background"
November 2015	Hawaii Society of Clinical Oncology (Honolulu, HI) Membership Conference "Colorectal Cancer: Biomarkers and Treatment"
November 2015	Mountain States Cancer Conference (Aurora, CO) "Treatment of Advanced Colorectal Cancer"
October 2015	"Year in Review", Research to Practice (Chicago, IL) "Emerging Data in the Management of Non-Colorectal GI Cancers"
August 2015	Mayo Clinic Scottsdale (Scottsdale, AZ) Oncology Grand Rounds: "Colon Cancer: Biomarkers and Treatment"
August 2015	Pancreatic and Biliary Educational Conference (Aurora, CO) "Sharing the Care: Collaborating with Community Providers"
June 2015	Chair and Content Developer, CME Lecture/Oncology Grand Rounds Current Guidelines and Future Directions in Colorectal Cancer Treatment Washington Hospital Center (Washington, DC) UCSF Fresno (Fresno, CA)
May 2015	1R25CA160013, Promoting Healthy Cancer Survivorship in Rural Colorado Primary Health Care Practices. iSurvive Webinar "Colon Cancer: Surveillance and Survivorship"
March 2015	21 st Annual NOCR Meeting (Las Vegas, NV) "The GI Malignancy Pipeline"
January 2015	ASCO/SSO/AGA Annual GI Cancers Symposium (San Francisco, CA) Moderator, "General Session 4: Ordering Molecular Profiling for Patients: Are We Ready?"
November 2014	Asia-Pacific Gastroenterology Cancer Summit 2014 (Singapore) Chair, Pancreatic Cancer Symposium Panelist, Multi-Disciplinary Tumor Board Lecturer, "How Biology Drives Optimal Treatment in CRC"
October 2014	National Comprehensive Cancer Network Webinar

October 2014	<p>“Challenges in Assessing and Using Biomarkers in Oncology Care” Massachusetts General Hospital Cancer Center (Boston, MA) Oncology Grand Rounds</p>
August 2014	<p>“Biomarker-Driven Trials in GI Cancers” Presenter, 24th Annual Mayo Heme/Onc Review (Jacksonville, FL) “Molecular Targets in Colorectal Cancer”</p>
July 2014	<p>Presenter, Oncology Grand Rounds (Dallas, TX) “Optimizing Care for Colorectal Cancer”</p>
June 2014	<p>Presenter, NCCN Lecture Series (Orange, CA) “NCCN Guidelines: Optimizing Treatment of Colorectal Cancer”</p>
June 2014	<p>Presenter, CancerNet (Chicago, IL) Webcast, “Overcoming KRAS Mutations in Colorectal Cancer”</p>
May 2014	<p>Presenter, “Research To Practice” (Chicago, IL)</p>
April 2014	<p>Webinar: Colorectal Cancer Treatment (Aurora, CO) Patient Navigation Training Webinar “Colorectal Cancer Treatment: Chemotherapy and Outcomes”</p>
March 2014	<p>CME Course: “Great Debates in GI Malignancies” (New York, NY) Chair, Satellite Symposium, “Drug Pipeline in GI Cancers” - “Drug Targets: FGFR, IGFR, cMet” - “Debate: Chemotherapy Backbones Are Irrelevant” - “Debate: Peri-Operative Therapy for Liver Metastases” - “Debate: Molecular Testing in Colorectal Cancer” - Panel Discussion: Challenging GI Cancer Cases”</p>
January 2014	<p>Oncology Society of Columbia (San Francisco, CA) “Biomarkers in Colorectal Cancer”</p>
November 2013	<p>Mountain States Cancer Conference (Aurora, CO) “Treatment of Advanced Colorectal Cancer”</p>
October 2013	<p>Online CME: CaseLink Series “Treatment for Refractory Colorectal Cancer”</p>
June 2013	<p>ASCO Annual Meeting (Chicago, IL) Poster Discussant, 9 abstracts</p>
June 2013	<p>ASCO Annual Meeting (Chicago, IL) Mock Study Section</p>
May 2013	<p>ASCO Annual Meeting Satellite Symposium “Improving patient outcomes by targeting the VEGF/VEGFR axis”</p>
April 2013	<p>School of Pharmacy/ Pharmaceutical Sciences Seminar “Novel Therapeutics for Gastrointestinal Tumors”</p>
April 2013	<p>CME Course: “Great Debates in GI Malignancies” (New York, NY) - “Novel Approaches to Her+ Gastric and GEJ Tumors” - “Debate: Taxanes as Standard of Care for 2nd line Gastric CA” - “Debate: Immunotherapy for GI Malignancies” - “Novel Therapies in GI Cancers: Met, Wnt, Notch”</p>
March 2013	<p>University of Colorado School of Medicine (Aurora, CO) Surgical Grand Rounds “Update in Management of Colorectal Cancer”</p>
February 2013	<p>University of Colorado School of Medicine (Aurora, CO) Clinicopathologic Correlation Conference “Pathology Reports: An Oncologist’s View”</p>
February 2013	<p>University of Colorado School of Medicine (Aurora, CO) 4th Year “Applied Pharmacology Course” “Management of Colorectal Cancer”</p>

January 2013	-Oncology Grand Rounds, Penn State Cancer Center (State College, PA) Johns Hopkins CME Program "Treatment of Advanced / Refractory Colorectal Cancer"
November 2012	-Oncology Grand Rounds, Rush Medical Center (Chicago, IL) Johns Hopkins CME Program "Treatment of Advanced / Refractory Colorectal Cancer"
October 2012	Oncology Grand Rounds (Chicago, IL) "Metastatic Colorectal Cancer Case Debates: Practical Solutions to Provide Optimal Management" John Stroger Hospital of Cook County
September 2012	Medical Resident Seminar Series (Aurora, CO) "How to Give an Excellent Presentation"
September 2012	International Society of Gastrointestinal Oncology (Alexandria, VA) Co-Chair, "Advanced Colorectal Cancer" session Co-Moderator, Case Discussion
April 2012	Johns Hopkins CME (Baltimore, MD) "Virtual Tumor Board: Colorectal Cancer"
March 2012	Fellows' Lecture (Aurora, CO) "Treatment of Advanced Colorectal Cancer"
February 2012	ASCO Webinar / ASCO University "Highlights from the 2012 Gastrointestinal Cancers Symposium"
February 2012	Yale Cancer Center (New Haven, CT) "Research in Progress" conference "Biomarker-Driven Studies in GI Cancers"
January 2012	UCSOM "Update in Liver Disease Management" (Denver, CO) "Hepatocellular Carcinoma: A Multi-Disciplinary Approach"
January 2012	ASCO/AGA/ACOSOG GI Symposium (San Francisco, CA) Chair, Scientific Program Committee, Colorectal Track Moderator, Translational Science Session
January 2012	ASCO/AGA/ACOSOG GI Symposium (San Francisco, CA) Chair, Satellite Symposium (Educational Concepts Group) "Gaps in Therapy and Supportive Care for CRC" "Multi-kinase Inhibition: Implications for Management"
December 2011	Mayo SPORE presentation (Rochester, MN) "Biomarker-Driven Studies in GI Cancers"
November 2011	Radiological Society of North America (RSNA; Chicago, IL) Annual Meeting – Refresher Course "Medical Management of HCC"
November 2011	Washington Cancer Center Grand Rounds (Washington, DC) "Community Debates in Colorectal Cancer"
October 2011	Department of Surgery Grand Rounds (Aurora, CO) "Evolving Treatments for Pancreas Cancer"
October 2011	9 th Annual West Coast Colorectal Cancer Symposium (Seattle, WA) "New Targets in Colorectal Cancer"
October 2011	Bethesda Naval Medical Center (Bethesda, MD) "Community Debates in Colorectal Cancer"
September 2011	International Society of Gastrointestinal Oncology (Alexandria, VA) "Using Biomarkers in Advanced Colorectal Cancer" Moderator, Case Presentation Session
July 2011	Medical Resident Seminar Series (Aurora, CO) "How to Give an Excellent Presentation"

- June 2011 Colon Cancer Alliance National Meeting (Denver, CO)
“New Treatment Options for Colorectal Cancer: What is on the Horizon?”
- June 2011 -Speaker, American Society of Clinical Oncology Annual Meeting (Chicago, IL), Education Session
“Toxicities of Chemotherapy for Colorectal Cancer”
- Panelist, American Society of Clinical Oncology Annual Meeting, Fellows’ Session “Obtaining Your First R01 Grant”
- March 2011 -Speaker and Panelist, “Debates and Updates in Gastrointestinal Malignancies” (New York, NY)
Panelist, “Challenging Colorectal Cancer Cases”
Speaker, “Is there a role for maintenance chemotherapy?”
Speaker, “What is optimal management of stage IV unresectable disease with intact primary?”
- March 2011 -Speaker, Medical Oncology Fellowship Lecture Series (Aurora, CO)
“Colorectal Cancer Trials You Need to Know”
- February 2011 -Invited Speaker, Kuwait Ministry of Health
First Regional Conference on Cancer Molecular Targeted Therapy
“Personalized Medicine in Colorectal Cancer” (Kuwait City, Kuwait)
- January 2011 -Moderator, Cancers of the Colon and Rectum: Translational Research
American Society of Clinical Oncology/SSO Gastrointestinal Symposium (San Francisco, CA)
- December 2010 -Speaker, Department of Surgery Grand Rounds (Aurora, CO)
“Predictive and Prognostic Tests in Colorectal Cancer”
- October 2010 -Speaker, VA Oncology Grand Rounds (Alexandria, LA; Daytona Beach, FL; Billings, MT)
“Management of Metastatic Colorectal Cancer”
- September 2010 -Speaker, International Society of Gastrointestinal Oncology
“Promising Agents in Gastrointestinal Cancers”
-Speaker, Gastrointestinal Grand Rounds (Aurora, CO)
“Pharmacodiagnosics in Colorectal Cancer”
- August 2010 Speaker, Clinical Investigations Shared Resources Group (Aurora, CO) “Advances in Management of Colorectal Cancer”
- July 2010 -Speaker, Medical Grand Rounds (Las Vegas, NV)
Southern Nevada VA Medical Center
“Management of Metastatic Colorectal Cancer”
-Speaker, Internal Medicine Residency Program (Aurora, CO)
“How to Give an Effective Presentation”
- June 2010 -Discussant, Schwartz Center Rounds (Aurora, CO)
University of Colorado Cancer Center
“Distress in Decision Making When Clinician Views Clash”
-Speaker, American Society of Clinical Oncology Annual Meeting (Chicago, IL)
-“Intracellular components of signal transduction pathways as therapeutic targets in colorectal cancer” (Educational Session)
- Discussant, Colorectal Cancer Poster Discussion Session (#17-25) (Chicago, IL)
- January 2010 Chair and Moderator, American Society of Clinical Oncology Gastrointestinal Symposium General Session V (Chicago, IL):

- Cancers of the Pancreas, Small Bowel, and Hepato-Biliary Tract: Translation Research (speakers: Tuveson, Dang, Jain)
- January 2010 Speaker, Fellows Conference (and Fellow Applicant Interview Day)
"Gastrointestinal Cancer Update: 2010" (Aurora, CO)
- October 2009 Speaker, Medical Grand Rounds (Kansas City, MO)
Kansas City Veteran's Administration Medical Center
"Individualization of Care in the Management of Metastatic Colorectal Cancer"
- October 2009 Speaker, Cancer Center Staff Meeting (Aurora, CO)
"Gastrointestinal cancer care: multidisciplinary and personalized"
- September 2009 Speaker, Colorado Cancer Day 2009 (Aurora, CO)
"Colorectal Cancer: Surveillance and Chemo Side Effects"
- September 2009 Speaker, Science and Practice of Transformative Therapies
"KRAS and other Pharmacodiagnosics for Colorectal and Lung Cancer" (Savannah, GA)
- July 2009 Presenter, Educational Dinner Meeting
Rocky Mountain Oncology Society (Denver, CO)
"2009 Update on Gastrointestinal Cancers: Focus on Pharmacodiagnosics"
- June 2009 Moderator, "Meet the Professor Session", 2009 American Society of Clinical Oncology Annual Meeting (Chicago, IL)
"Neoadjuvant and Adjuvant Chemotherapy for Hepatic Colorectal Cancer Metastases: When to Use It" (Orlando, FL)
- April 2009 Plenary Session Discussant, American Association for Cancer Research Annual Meeting (Denver, CO)
"Discussion of Abstract LB-93: BRAF, PI3K, KRAS, and loss of PTEN impair response to EGFR-targeted therapies in metastatic colorectal cancer" ("Plenary: Spotlight on Breakthroughs in Cancer Research")
- April 2009 Speaker, Oncology Tumor Board, Deaconess Medical Center
"Management of Advanced Colorectal Cancer: Patient Selection and Optimization of Care" (Spokane, WA)
- April 2009 Schwartz Center Rounds (Aurora, CO)
Presenter/Discussant: "Who Comes First: Challenges of Personal and Professional Boundaries"
- April 2009 Speaker, "Great Debates and Updates in Gastrointestinal Malignancies" (New York, NY)
Debate: "Chemotherapy Followed by Surgery for Resectable Colorectal Liver Metastases"
Debate: "Calcium and Magnesium Infusions Are Not an Appropriate Approach to the Prevention of Platinum-Induced Neurotoxicity"
- March 2009 Speaker, Society for Interventional Radiology Satellite Symposium
"Advances in Medical Therapies for Hepatocellular Cancer" (San Diego, CA)
- December 2008 Speaker, University of Colorado Cancer Center Fellow Lecture Series (Aurora, CO)
"Neo-Adjuvant and Adjuvant Therapy for Colorectal Cancer"
- December 2008 Speaker, University of Colorado Cancer Center Fellow Lecture Series (Aurora, CO)
"Management of Advanced Colorectal Cancer"

November 2008	Speaker, Clinical Investigations Shared Resources Lecture Series (Aurora, CO) "Management of Colorectal Cancer"
October 2008	Moderator, University of Colorado Cancer Center conference series (Aurora, CO) "Debates in Colorectal Cancer 2008" (Ken Tanabe, MD)
October 2008	Speaker, Johns Hopkins Cancer Center Webinar (Bethesda, MD) "Optimizing Treatment of Colorectal Cancer for Community Oncologists"
June 2008	Moderator, "Metastatic Colorectal Cancer: Still a Shifting Paradigm" (Lee Ellis, MD) "Biomarkers in Colorectal Cancers"
June 2008	Speaker, "Advances in Cancer Diagnostics" (Denver, CO) "Colorectal Cancer: Management and Diagnostics (KRAS)"
May 2008	Speaker, Medicine Grand Rounds, University of Colorado (Aurora, CO) "Management of Colorectal Cancer"
May 2008	Speaker, Kaiser Permanente Oncology Rounds (Denver, CO) "Update on University of Colorado Cancer Center Phase I and Gastrointestinal Programs"
April 2008	Speaker, Surgery Grand Rounds, University of Colorado (Aurora, CO) "Peri-Operative Chemotherapy: Promise and Pitfalls"
March 2008	Plenary Session Speaker, Society of Interventional Radiology (Washington, D.C.) Annual Meeting; Interventional Oncology Session "New Systemic Targeted Agents for HCC: Is There a Synergy with Locoregional Approaches?"
February 2008	Shawnee Mission Medical Center, Grand Rounds (Kansas City, KS) "Treatment for Colorectal Cancer: A Shifting Paradigm"
January 2008	University of Colorado Cancer Center (Aurora, CO) Moderator, Cancer Lecture Series, "Using Available Databases for Colorectal Cancer Research"
November 2007	University of Colorado Cancer Center (Aurora, CO) Moderator, Journal Club, "Treatment of Rectal Cancer"
November 2007	University of Colorado Cancer Center (Aurora, CO) Phase I Review Presentation, "Src Inhibitors"
November 2007	University of Colorado Cancer Center (Aurora, CO) Fellows' Presentation, "Treatment of Colorectal Cancer"
January 2007	7 th Annual Oncology Update: Advances and Controversies, (Steamboat Springs, CO) Invited Speaker
November 2006	Bergen Mercy Medical Center (Omaha, NE) Invited Speaker (Continuing Medical Education)
October 2006	Johns Hopkins University, School of Medicine (Baltimore, MD) Invited Speaker (Continuing Medical Education)
September 2006	Cancer Education Consortium Clinical Pharmacology Workshop (Leesburg, VA), Invited Speaker
June 2006	Grand Rounds, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD), Invited Speaker (Continuing Medical Education)
June 2006	World Conference on Interventional Oncology (Cernobbio, Italy)

April 2006	Invited Speaker (Continuing Medical Education) Grand Rounds, Upper Chesapeake Health Center (Bel Air, MD)
March 2006	Invited Speaker (Continuing Medical Education) Oncology Grand Rounds, Greater Baltimore Medical Center (Towson, MD), Invited Speaker (Continuing Medical Education)
February 2006	Continuing Medical Education Review Course, Fairfax Inova Health System (Falls Church, VA), Keynote Speaker
January 2006	American Hepato-Pancreato-Biliary Association (San Francisco, CA), Invited Speaker (Continuing Medical Education)
September 2005	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD), Invited Speaker (Continuing Medical Education)
September 2005	Cancer Education Consortium Clinical Pharmacology Workshop (Leesburg, VA), Invited Speaker
June 2005	Grand Rounds, Virginia Medical Center (Fairfax, VA) Invited Speaker (Continuing Medical Education)
June 2005	St. Agnes Cancer Center (Baltimore, MD) Invited Speaker (Continuing Medical Education)
May 2005	American Society of Clinical Oncology/Society for Interventional Radiology (London, England) Invited Speaker/Moderator
March 2005	Johns Hopkins School of Medicine jointly with Institute for Johns Hopkins Nursing (Baltimore, MD), Invited Speaker (Continuing Medical Education)
April 2005	Johns Hopkins School of Medicine jointly with Institute for Johns Hopkins Nursing (Baltimore, MD), Invited Speaker (Continuing Medical Education)
September 2004	Cancer Education Consortium Clinical Pharmacology Workshop (Leesburg, VA), Invited Speaker
September 2004	Johns Hopkins Department of Surgery (Baltimore, MD) Invited Speaker (Continuing Medical Education)
August 2004	Johns Hopkins Colon Cancer Center (Baltimore, MD) Invited Speaker and Panelist
June 2004	Oncology Nursing Society Meeting (Baltimore, MD) Invited Speaker (Continuing Medical Education)
February 2004	National Cancer Institute/Cancer Therapy Evaluation Program Early Drug Development Meeting, National Cancer Institute (Bethesda, MD), Invited Speaker
January 2004	Gastrointestinal Cancer Conference, Dana-Farber/Brigham and Women's Cancer Center (Boston, MA), Invited Speaker
January 2004	Chief's Conference, Massachusetts General Hospital Cancer Center (Boston, MA), Invited Speaker
January 2004	Research Conference, University of Colorado School of Medicine (Aurora, CO), Invited Speaker
March 2003	National Cancer Institute/Cancer Therapy Evaluation Program Early Drug Development Meeting (Bethesda, MD), Invited Speaker

PUBLICATIONS

(223 publications listed on PubMed; as of 7/2025, >24,339 citations in Google Scholar; h-index=78, i10 index 225). Abstracts available upon request.

PEER-REVIEWED SCIENTIFIC ARTICLES

1. Lincoln J and Messersmith WA, Conditions required for the measurement of nitric oxide synthase activity in a myenteric plexus/smooth muscle preparation from the rat ileum. *Journal of Neuroscience Methods* 1995;59: 191-197.
2. O'Hanlon TP, Messersmith WA, Dalakas MC, Plotz PH, and Miller FW, Gamma-delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *Clinical Experimental Immunology* 1995;100: 519-528.
3. Bieganowska KD, Messersmith WA, Anderson D, Slovik E, and Hafner DA, T-cell receptor analysis of human T-cell clones. *The Immunologist* 1996;4(1): 12-13.
4. Bieganowska KD, Ausubel LJ, Modabbar Y, Slovik E, Messersmith WA, and Hafner DA, Direct ex vivo analysis of activated fas-sensitive autoreactive T cells in human autoimmune disease. *Journal of Experimental Medicine* 1997;185(9): 1585-1594.
5. Messersmith WA, Brown DFM, and Barry MJ, The prevalence and implications of incidental findings on emergency department abdominal CT scans. *American Journal of Emergency Medicine* 2001;19(6): 479-481.
6. Messersmith WA, Laheru DL, Senzer N, Donehower RC, Grouleff P, Kelley S, and Hidalgo M, Phase I trial of irinotecan, infusional 5-FU, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. *Clinical Cancer Research* 2004; 10:6522-6527.
7. Messersmith W, Oppenheimer O, Peralba J, Sebastiani V, Amador M, Jimeno A, Embuscado E, Hidalgo M, Iacobuzio-Donahue C, Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. *Cancer Biology and Therapy* 2005;4(12): 1381 – 1386.
8. Rudek MA, Zhao M, Smith IF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, and Baker SO, In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. *Clinical Cancer Research* 2005;11 (23): 8503-11.
9. Rudek MA, Zhao M, He P, Zabelina Y, Jin R, Messersmith WA, Wolff AC, Baker SD, Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences* 2005;15;828(1-2):41-54.
10. Messersmith WA, Baker SO, Lassiter L, Sullivan RA, Oin K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, and Almstrong OK, Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. *Clinical Cancer Research* 2006; 12: 1270-75.
11. Li J, Brahmer J, Messersmith WA, Hidalgo M, Baker SD, Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. *Investigational New Drugs* 2006 Jul;24(4):291-7.
12. Kamel I, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes OK, Geschwind JF, The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology* 2006 Mar; 17(3):505-12.
13. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikali C, Shi C, Oanenberg K, Danenberg PV, Kuramochi H, Tanak K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiock S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M. An in vivo Platform for Translational drug Development in Pancreatic Cancer. *Clinical Cancer Research* 2006 Aug; 1; 12(15):4652-61.
14. Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BO, Messersmith WA, Baker SD. A rapid and sensitive method for determination of sorafenib in human plasma

- using a liquid chromatography/tandem mass spectrometry assay. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*. 2007 Feb 1;846(1-2):1-7.
15. Rudek MA, Zhao M, He P, Messersmith WA, Baker SO. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. *Journal of Pharmaceutical and Biomedical Analysis* 2006 Sep 18;42(2):253-60.
 16. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC, Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumors. *European Journal of Cancer* 2006;43(1):78-86.
 17. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M, Assessment of celecoxib pharmacodynamics in pancreatic cancer. *Molecular Cancer Therapeutics* 2006;5(12):3240-7.
 18. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC, Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. *Cancer Chemotherapy and Pharmacology* 2007 Apr 12; [Epub ahead of print].
 19. Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. *Ann Oncol*. 2008 Feb;19(2):374-9.
 20. Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansley D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2008;63(1):181-8.
 21. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, and Hidalgo M, Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. *Cancer Res* 2008;68 2841-2849.
 22. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Basterman JM, Martell RE, Carducci MA, Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. *J Clin Oncol* 2008;26(12):1940-1947.
 23. Aboumater HJ, Winner LE, Davis RO, Trovitch PB, Berg MM, Violette KM, Messersmith WA, Maylor KK, Lehmann CU. No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system. *Am J Manag Care*. 2008 May;14(5):309-16.
 24. Baker S, Verweij J, Cusatis G, van Schaik R, Marsh S, Orwick S, Franke R, Hu S, Schuetz E, Lamba V, Messersmith W, Wolff A, Carducci M, Sparreboom A. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. *Clin Pharmacol Ther*. 2009;85(2):155-63.
 25. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. *Clin Cancer Res*. 2008;14(17):5602-9.
 26. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. *J Clin Oncol*. 2008;26(25):4172-9.

27. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC, Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. *J Clin Oncol*. 2008;26(34):5504-10.
28. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy. *J Clin Oncol*. 2009 Jun 1;27(16):2697-704. Epub 2009 Apr 20.
29. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, and Hidalgo M, Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. *Clin Can Res* 2009 Jun 15;15(12):4138-46 [PMC - in process].
30. Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, and Hidalgo M, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. *Mol Can Ther* 2009 Jun;8(6):1484-93. [PMC - in process].
31. Diaz LA Jr, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M, Eisenberger M, TNF-blockade in patients with advanced hormone refractory prostate cancer. *Invest New Drugs*. 2009 Oct 21. [Epub ahead of print].
32. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, and Messersmith WA, KRAS Mutation: Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer. *J Mol Diagn*. 2010 Jan;12(1):43-50. Epub 2009 Dec 10.
33. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR, A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. *Invest New Drugs*. 2010 Jan 19. [Epub ahead of print].
34. Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA, Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. *Invest New Drugs*. 2010 Mar 23. [Epub ahead of print].
35. Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA, Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. *Clin Cancer Res*. 2010 Aug 15;16(16):4165-77. Epub 2010 Aug 3.
36. Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG. Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in KRAS-Mutated Colorectal Cancer. *Mol Cancer Ther*. 2010 Oct 5. [Epub ahead of print].
37. Infante JR, Jones SF, Bendell JC, Spigel DR, Yardley DA, Weekes CD, Messersmith WA, Hainsworth JD, Burris HA 3rd, A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. *Eur J Cancer*. 2010 Nov 2. [Epub ahead of print].
38. Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak E, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor CF, Messersmith WA, Shapiro Gastrointestinal. Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2010 Dec 3. [Epub ahead of print].
39. Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A Tolerability and Pharmacokinetic

- Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer. *Transl Oncol.* 2010 Dec 1;3(6):373-379.
40. Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. *Clin Colorectal Cancer.* 2010 Dec;9(5):297-304.
 41. Burakgazi AZ, Messersmith WA, Vaidya D, Hauer P, Hoke A, Polydefkis M, Longitudinal assessment of oxaliplatin-induced neuropathy. *Neurology.* 2011 Aug 24. [Epub ahead of print].
 42. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA, Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2011 Dec 16. [Epub ahead of print]
 43. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhem F, Eckhardt SG, Adjeii AA, Jimeno A, Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. *Clin Cancer Res.* 2012 Feb 14. [Epub ahead of print]
 44. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. *Invest New Drugs.* 2012 Mar 14. [Epub ahead of print]
 45. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH(+) tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ -secretase inhibitor and irinotecan in colorectal cancer. *Mol Oncol.* 2012 Mar 28. [Epub ahead of print]
 46. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. *J Clin Oncol.* 2012 Apr 23. [Epub ahead of print]
 47. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. *Invest New Drugs.* 2012 May 22. [Epub ahead of print]
 48. Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2012 May 24. [Epub ahead of print]
 49. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A Multicenter Phase 1 Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2012 Jun 12. [Epub ahead of print]
 50. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R,

- Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. *Lancet Oncol.* 2012 Aug;13(8):782-9. Epub 2012 Jul 16.
51. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, Demarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. *Lancet Oncol.* 2012 Aug;13(8):773-81. Epub 2012 Jul 16.
 52. Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. *Front Pharmacol.* 2013;4:35. doi: 10.3389/fphar.2013.00035. Epub 2013 Mar 28.
 53. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. *Cancer Med.* 2012 Oct;1(2):207-17
 54. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *Cancer.* 2013 Mar 1;119(5):1042-9.
 55. Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1 α mediates resistance to mTOR-directed therapy in pancreatic cancer. *Neoplasia.* 2012 Aug;14(8):690-701.
 56. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *Cancer.* 2013 Mar 1;119(5):1042-9
 57. Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. *Front Pharmacol.* 2013;4:35. Epub 2013 Mar 28.
 58. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehr DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. *Mol Oncol.* 2013 Apr 4
 59. Ray CE Jr, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, Rochon PJ, Gupta R, Messersmith W, Purcell T, Durham J. Metaanalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangiocarcinoma. *J Vasc Interv Radiol.* 2013 May 28
 60. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips K, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. *Clin Cancer Res.* 2013 Jun 11. [Epub ahead of print]
 61. Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA. Tumours with elevated levels of the Notch and Wnt pathways exhibit

- efficacy to PF-03084014, a γ -secretase inhibitor, in a preclinical colorectal explant model. *Br J Cancer*. 2013 Aug 6;109(3):667-75. Epub 2013 Jul 18.
62. Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Kozloff MF. A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2013 Dec;12(4):248-54. Epub 2013 Sep 27
 63. Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A, Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. *Clin Cancer Res*. 2014 Mar 15;20(6):1656-65
 64. Patnaik A, Lorusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD, Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2014 Mar 17. [Epub ahead of print]
 65. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W, A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. *Invest New Drugs*. 2014 Aug;32(4):739-45
 66. Ney DE, Messersmith W, Behbakht K. Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical cancer. *J Clin Neurol*. 2014 Jul;10(3):262-6.
 67. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A Phase I, Dose-finding Study in Patients With Advanced Solid Malignancies of the Oral Gamma-Secretase Inhibitor PF-03084014. *Clin Cancer Res*. 2014 Sep 17 [Epub ahead of print]
 68. Song EK, Tai W, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. *Int J Cancer*. 2014 Sep 20 [Epub ahead of print]
 69. Li L, Abraham AD, Zhou Q, Ali H, O'Brien JV, Hamill BD, Arcaroli JJ, Messersmith WA, LaBarbera DV. An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase II α and Potent Anticancer Agent. *Mar Drugs*. 2014 Sep 19 [Epub ahead of print]
 70. Hochster HS, Uboha N, Messersmith W, Gold PJ, O'Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. *Cancer Chemother Pharmacol*. 2014 Oct 17. [Epub ahead of print]
 71. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2014 Nov 11 [Epub ahead of print]
 72. Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. *PLoS One*. 2014 Nov 17;9(11):e113037.
 73. Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (DII4)

- Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Feb 27. [Epub ahead of print]
74. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/ β -Catenin, Notch and PI3K/Akt Signaling Pathways. PLoS One. 2015 May 7;10(5):e0121648
 75. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 1;21(11):2462-70
 76. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Sep;26(9):1923-9.
 77. Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Front Pharmacol. 2015 Jun 16;6:120.
 78. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2015 Jul 7.
 79. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Sep 21.
 80. Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget. 2015 Oct 1.
 81. Singh S, Arcaroli JJ, Orlicky DJ, Chen Y, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Thompson DC, Vasiliou V. Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. Pancreas. 2015 Nov 12
 82. Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016 Jan 19
 83. Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2015 Dec 30
 84. Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase I Study of ABT-751 in Combination

- with CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients with Advanced Colorectal Cancer. *J Clin Pharmacol*. 2015 Dec 3.
86. Zhou Q, Abraham AD, Li L, Babalmorad A, Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL, Schaack J, Messersmith WA, LaBarbera DV. Topoisomerase II α mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. *Oncogene*. 2016 Mar 7.
 87. Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. *Oncotarget*. 2016 Apr 7.
 88. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung JA, Wyant T, Fasanmade A, Messersmith WA, Rodon J. Phase I study of the investigational anti-guanlyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. *Clin Cancer Res*. 2016 May 13
 89. Chapman BC, Paniccia A, Hosokawa PW, Henderson WG, Overbey DM, Messersmith W, McCarter MD, Gleisner A, Edil BH, Schulick RD, Gajdos C. Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients undergoing Hepatic Resection for Hepatocellular Carcinoma. *J Am Coll Surg*. 2016 Dec 3: S1072-7515(16)31671-4.
 90. Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J. Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. *J Vis Exp*. 2016 Sep 30;(115).
 91. Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. *J Natl Cancer Inst*. 2016 Sep 15;109(1).
 92. Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. *Oncotarget*. 2016 Aug 2;7(31):50290-50301.
 93. Chapman BC, Hosokawa P, Henderson W, Paniccia A, Overbey DM, Messersmith W, Lieu C, Stiegmann GV, Schulick RD, Gajdos C. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. *J Surg Oncol*. 2017 Mar 23.
 94. Bardia A, Mayer IA, Diamond JR, Moroosse RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. *J Clin Oncol*. 2017 Mar 14.
 95. Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. *Invest New Drugs*. 2017 Apr;35(2):235-241.
 96. Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. *Clin Cancer Res*. 2017 Jul 5

97. Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Scheffer T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. *Pancreas*. 2017 Aug;46(7):904-912.
98. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. *J Clin Oncol*. 2017 Aug 17.
99. Matsumoto A, Arcaroli J, Chen Y, Gasparetto M, Neumeister V, Thompson DC, Singh S, Smith C, Messersmith W, Vasiliou V. Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer. *Br J Cancer*. 2017 Sep 7.
100. Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. *Ann Surg Oncol*. 2017 Sep 8.
101. Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2017 Sep 27
102. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff DD. Phase 1 study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. *Mol Cancer Ther*. 2017 Oct 20.
103. Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. *PLoS One*. 2017 Nov 1;12(11):e0187173. PMC5665512
104. Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. *Oncologist*. 2018 Aug 23. [Epub ahead of print] PMID: 30139840
105. Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. *Anticancer Drugs*. 2018 Jul 25. [Epub ahead of print] PMID: 30048249
106. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippe S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. *Cancer Res*. 2018 Jul 24. [Epub ahead of print] PMID: 30042150
107. Scott AJ, Arcaroli JJ, Bagby SM, Yahn R, Huber KM, Serkova NJ, Nguyen A, Kim J, Thorburn A, Vogel J, Quackenbush KS, Capasso A, Schreiber A, Blatchford P, Klauck PJ, Pitts TM, Eckhardt SG, Messersmith WA. Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms. *Mol Cancer Ther*. 2018 Jul 19 [Epub ahead of print] PMID: 30026382
108. Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, Meguid C, Gajdos C, McCarter MD, Schulick RD, Edil BH. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. *JOP*. 2018 Mar;19(2):75-85. Epub 2018 Mar 30. PMID: 29950957
109. Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, Eckhardt SG, Cadogan EB, Hughes GD, Smith A,

- Pitts TM, Arcaroli JJ. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. *Oncotarget*. 2017 Dec 5;8(67):110904-110913. eCollection 2017 Dec 19. PMID: 29340025
110. King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, [Messersmith WA](#), El-Khoueiry AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. *Invest New Drugs*. 2018 Jan 15. [Epub ahead of print] PMID: 29333575
 111. Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, Krishnan, Kutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, [Messersmith WA](#), Fujita M. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. *Cancer Res*. 2018 Dec 1;78(23):6561-6574
 112. Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, [Messersmith WA](#), Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. *J Clin Endocrinol Metab*. 2019 Sep 12. [Epub ahead of print]. PMID: 31513709.
 113. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, [Messersmith WA](#), LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. *J Med Chem*. 2019 Nov 27. PMID: 31675229.
 114. Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, [Messersmith WA](#), LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L With Preclinical Activity Against Colorectal Cancer. *Mol Cancer Ther*. 2020 Jun 4
 115. Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, [Messersmith WA](#), Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase 1 Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. *Clin Cancer Res*. 2020 May 15:
 116. O'Hara MH, [Messersmith W](#), Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng SB, Vangerow B, Khan AA, Koneru M, Wang-Gillam A. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. *J Pancreat Cancer*. 2020 Mar 12;6(1):21-31.
 117. Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, [Messersmith WA](#), Eckhardt SG, Diamond JR. Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. *Cancers (Basel)*. 2020 Mar 19;12(3):719.
 118. Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, Phan A, Bickett T, Jordan K, Proia T, Schulick R, [Messersmith WA](#), Del Chiaro M, Clambey E, Gough MJ, Williams J, Hansen K, Goodman K, Karam SD. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. *Cancer Immunol Immunother*. 2020 ePub Oct 23.
 119. Anthony L, Atweh G, Bhatia R, Carey LA, Chang JC, Edelman MJ, Kantoff PW, Markham MJ, [Messersmith W](#), Nelson EL, Oettel K, O'Regan R, Verschraegen CF, Vose JM. Benchmarks for Academic Oncology Faculty. *JCO Oncol Pract*. 2020 ePub Sep 30
 120. Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, [Messersmith WA](#), Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. *Mol Carcinog*. 2020 Oct;59(10):1227-1240.
 121. Dotan E, Cardin DB, Lenz HJ, [Messersmith W](#), O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. *Clin Cancer Res*. 2020 Oct 15;26(20):5348-5357

122. Zakem SJ, Mueller AC, Meguid C, Torphy RJ, Holt DE, Schefter T, [Messersmith WA](#), McCarter MD, Del Chiaro M, Schulick RD, Goodman KA. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. *HPB (Oxford)*. 2020 Dec 1
123. Mueller AC, Piper M, Goodspeed A, Bhuvane S, Williams JS, Bhatia S, Phan AV, Van Court B, Zolman KL, Peña B, Oweida AJ, Zakem S, Meguid C, Knitz MW, Darragh L, Bickett TE, Gadwa J, Mestroni L, Taylor MRG, Jordan KR, Dempsey P, Lucia MS, McCarter MD, Del Chiaro M, [Messersmith WA](#), Schulick RD, Goodman KA, Gough MJ, Greene CS, Costello JC, Galvao Neto A, Lagares D, Hansen KC, Van Bokhoven A, Karam SD. Induction of ADAM10 by RT drives fibrosis, resistance, and EMT in pancreatic cancer. *Cancer Res*. 2021 Feb 1
124. Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, [Messersmith WA](#), Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. *Front Immunol*. 2021 Mar 29
125. Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, [Messersmith W](#), Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. *Front Oncol*. 2021 Mar 10
126. Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, Eckhardt SG, [Messersmith WA](#), Pitts TM. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. *Front Oncol*. 2021 Mar 25
127. Esquer H, Zhou Q, Nemkov T, Abraham AD, Rinaldetti S, Chen YC, Zhang X, Orman MV, D'Alessandro A, Ferrer M, [Messersmith WA](#), LaBarbera DV. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. *Oncogene*. 2021 Apr;40(16):2884-2897
128. Bardia A, [Messersmith WA](#), Kio EA, Berlin JD, Vahdat L, Masters GA, Moroosse R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. *Ann Oncol*. 2021 Jun;32(6):746-756
130. Oba A, Wu YHA, Lieu CH, Meguid C, Colborn KL, Beaty L, Al-Musawi MH, Davis SL, Leal AD, Purcell T, King G, Wooten ES, Fujiwara Y, Goodman KA, Schefter T, Karam SD, Gleisner AL, Ahrendt S, Leong S, [Messersmith WA](#), Schulick RD, Del Chiaro M. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. *Br J Surg* 2021 Jun 22
131. Piper M, Van Court B, Mueller A, Watanabe S, Bickett T, Bhatia S, Darragh LB, Mayeda M, Nguyen D, Gadwa J, Knitz M, Corbo S, Morgan R, Lee JJ, Dent A, Goodman K, [Messersmith W](#), Schulick R, Del Chiaro M, Zhu Y, Kedi RM, Lenz L, Karam SD. Targeting Treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma. *Clin Cancer Res* 2021 Dec 3
132. Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, [Messersmith WA](#). Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. *Lancet Oncol*. 2021 Dec;22(12):1740-1751.
133. Meric-Bernstam F, Sweis RF, Hodi FS, [Messersmith WA](#), Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-

- Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas. *Clin Cancer Res* 2021 Oct 29
134. Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or piasclisib in advanced solid tumors: a phase I study. *J Immunother Cancer* 2022 Mar;10(3):e004223.
 135. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. *J Med Chem*. 2022 Mar 10;65(5):3943-3961
 136. Hong ES, Messersmith WA, Hammad H, Cornish TC, Aisner DL. Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing. *JCO Precis Oncol*. 2022 Oct;6:e2200252.
 137. Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. *BMC Cancer*. 2022 Oct 29;22(1):1107.
 138. Lang J, Leal AD, Marín-Jiménez JA, Hartman SJ, Shulman J, Navarro NM, Lewis MS, Capasso A, Bagby SM, Yacob BW, MacBeth M, Freed BM, Eckhardt SG, Jordan K, Blatchford PJ, Pelanda R, Lieu CH, Messersmith WA, Pitts TM. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. *Front Oncol*. 2022 Nov 7;12:877635
 139. Lai SH, Vogel JD, Vemuru S, Messersmith W, Lieu C, McCarter M, Birnbaum E, Chapman BC. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients with Pathologic Complete Response. *Dis Colon Rectum* 2023 Jan 4
 140. Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. *Cancer Res Commun*. 2022 Nov 2;2(11):1326-1333.
 141. Scott AJ, Basu Mallick A, Dotan E, Cohen SJ, Gold PJ, Hochster HS, Subramaniam S, Barzi A, Watts GS, Blatchford PJ, Messersmith WA. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). *Cancer Res Commun*. 2022 Oct 14;2(10):1188-1196.
 142. Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith WA. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. *ESMO Open*. 2023 Jun 26;8(4):101584.
 143. Stuart CM, Kirsch MJ, Zhuang Y, Meguid CL, Sugawara T, Colborn KL, Messersmith W, Lieu C, Gleisner AL, Del Chiaro M, Schulick RD, Meguid RA. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. *Surgery*. 2023 Jun 28 (online)
 144. Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. *Cancer Res Commun*. 2023 Sep 20;3(9):1899-1911.
 145. Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Ruste SA, Haun A, Kawabe T. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. *Eur J Cancer*. 2024 Feb 22;201:113950.

146. Osorio D, Capasso A, Eckhardt SG, Giri U, Somma A, Pitts TM, Lieu CH, Messersmith WA, Bagby SM, Singh H, Das J, Sahni N, Yi SS, Kuijjer ML. Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data. *Nat Comput Sci*. 2024 Mar 4.
147. Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, Lentz RW, Lieu CH, Leal AD, Messersmith WA, Dempsey PJ, Pitts TM. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). *PLoS One*. 2024 Apr 10;19(4):e0298808.
148. Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Jordan KR, Serkova NJ, Pitts TM, Diamond JR. A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. *Cancers (Basel)*. 2024 Apr 10;16(8):1456.
149. Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, Lieu CH. A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer. *Clin Cancer Res*. 2024 Jun 13.
150. Singh S, Dafoe A, Cagle J, Messersmith WA, Kessler ER, Lum HD, Holliman BD, Fischer S. Respect for the Patient-Oncologist Relationship May Limit Serious Illness Communication by Acute and Postacute Care Clinicians After Discharge to a Skilled Nursing Facility. *JCO Oncol Pract*. 2024 Jun 10
151. Leary JB, Hu J, Leal A, Davis SL, Kim S, Lentz R, Friedrich T, Herter W, Messersmith WA, Lieu CH. Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer. *JCO Oncol Pract*. 2024 Jul 24:OP2400159.
152. Stoop TF, Oba A, Wu YHA, Beaty LE, Colborn KL, Janssen BV, Al-Musawi MH, Franco SR, Sugawara T, Franklin O, Jain A, Saiura A, Sauvanet A, Coppola A, Javed AA, Groot Koerkamp B, Miller BN, Mack CE, Hashimoto D, Caputo D, Kleive D, Sereni E, Belfiori G, Ichida H, van Dam JL, Dembinski J, Akahoshi K, Roberts KJ, Tanaka K, Labori KJ, Falconi M, House MG, Sugimoto M, Tanabe M, Gotohda N, Krohn PS, Burkhart RA, Thakkar RG, Pande R, Dokmak S, Hirano S, Burgdorf SK, Crippa S, van Roessel S, Satoi S, White SA, Hackert T, Nguyen TK, Yamamoto T, Nakamura T, Bachu V, Burns WR, Inoue Y, Takahashi Y, Ushida Y, Aslami ZV, Verbeke CS, Fariña A, He J, Wilmink JW, Messersmith W, Verheij J, Kaplan J, Schulick RD, Besselink MG, Del Chiaro M. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. *JAMA Netw Open*. 2024 Jun 3;7(6):e2417625
153. Andrew L. Coveler, Matthew J. Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz-Sarvise, Adnan Nagrial, Nataliya V. Uboha, Sophia Frentzas, Michael Overman, Anne Noonan, Wells A. Messersmith, Nick Pavlakis, Niharika B. Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A. Bielska, Veronique Bragulat, Zachary A. Cooper, Rakesh Kumar, David R. Spigel; A Phase 1b/2 Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res* 2024.
154. Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. *Int J Mol Sci*. 2024 Dec 7;25(23):13160.
155. Stoop TF, Sugawara T, Oba A... Messersmith W, Wilmink JW, Burkhart RA, Del Chiaro M, Besselink MG. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. *JAMA Oncol*. 2025 Mar 1;11(3):276-287.
156. Rangelova E, Stoop TF, van Ramshorst TME... Messersmith W, Wilmink JW, Abu Hilal M, Besselink MG, Del Chiaro M. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. *Ann Oncol* 2025 Jan 13:S0923-7534

157. Stoop TF, Wu YHA, Oba A... Messersmith W, Besselink MG, Burkhart RA, Wilmink JW, Del Chiaro M. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study. *Br J Cancer*. 2025 May 6.
158. Kim TM, Lakhani NJ, Soumerai J, Kamdar M, Gainor JF, Messersmith W, Fanning P, Guan S, Jin F, Forgie A, Wan HI, Pons J, Randolph SS, Kim WS. Evorpaccept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. *Haematologica*. 2025 Apr 10.
159. Gerber DE, Khushalani NI, Gao A, Zhang S, Clark JW, Messersmith WA, Benson AB, Puzanov I, Hayes DN, Zion NA, Heinrichs T, Berlin JD. Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians. *J Natl Compr Canc Netw*. 2025 Jul 11:1-6

INVITED REVIEWS AND EDITORIALS

1. Messersmith WA, Laharu D, Hidalgo M, Recent advances in the pharmacological treatment of colorectal cancer. *Expert Opinion on Investigational Drugs* 2003;2(3): 423-434.
2. Hidalgo M and Messersmith WA, Pharmacodynamic studies in drug development. American Society of Clinical Oncology 2004 Educational Book.
3. Messersmith WA, Laheru D, Eckhauser FE, Cetuximab in combination with gemcitabine for advanced pancreatic cancer: a commentary. *American Journal of Oncology Review* 2005;4(1):4245.
4. Makary MA, Messersmith WA, Eckhauser, FE, Review of combination gemcitabine and capecitabine in patients with advanced biliary cancer. *American Journal of Oncology Review* 2005; 4 (10) 640-641.
5. Messersmith WA, Chemotherapy agents for advanced colorectal cancer. Epocrates.com 2005.
6. Ma WW and Messersmith WA, CEA Monitoring in Colorectal Cancer: commentary. *Oncology* 2006;20(6):588-594.
7. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. *Annals of Surgical Oncology* 2006 Oct; 13(10): 1284-92.
8. Messersmith WA, Hidalgo MH, Carducci M, and Eckhardt SG, Novel Targets in Solid Tumors: MEK Inhibitors. *Clinical Advances in Hematology/Oncology* 2006;4(11):831-6.
9. Ma WW and Messersmith WA, Palliative Treatment of Metastatic Colorectal Cancer in the Era of Biologic Therapy: commentary. *Oncology* 2007:21 (5):566-577.
10. Crawford J, Althaus B, Annitage J, Balducci L, Bennett C, Blayney OW, Cataland SR, Dale DC, Demelji GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*. 2007 Feb;5(2): 188-202.
11. Messersmith WA and Hidalgo M, Panitumumab, a monoclonal anti-EGFR antibody in colorectal cancer: another one or the one? *Clinical Cancer Research* 2007:15;13(16):4664-6.
12. Nallapareddy S, Eckhardt G, and Messersmith W, Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: why do the results differ? *Current Colorectal Cancer Reports* 2008;4(3):167-172.
13. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. *N Engl J Med*. 2008;359(17):1834-6.

14. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection. *J Clin Oncol*. 2009 Mar 1;27(7):1130-6.
15. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer. *Cancer J*. 2009 Mar-Apr;15(2):110-3.
16. Leong S, Messersmith WA, Tan AC, Eckhardt SG. Novel agents in the treatment of metastatic colorectal cancer. *Cancer J*. 2010 May-Jun;16(3):273-82.
17. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. *Clin Cancer Res*. 2010 Aug 1;16(15):3811-8. Epub 2010 Jun 16.
18. Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W Jr, Zook J, Konski AA. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. *Curr Probl Cancer*. 2010 May-Jun;34(3):201-10.
19. Puls LN, Eadens M, Messersmith WA. Current Status of Src Inhibitors in Solid Tumor Malignancies. *Oncologist* 2011;16(5):566-78. Epub 2011 Apr 26.
20. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. *Oncology (Williston Park)*. 2010 Dec;24(14):1329-34.
21. Thompson C, Leong S, Messersmith WA. Promising targets and drugs in development for colorectal cancer. *Semin Oncol*. 2011 Aug;38(4):588-97.
22. Puls LN, Eadens M, Messersmith WA. Current status of SRC inhibitors in solid tumor malignancies. *Oncologist*. 2011;16(5):566-78. Epub 2011 Apr 26.
23. Berge E, Thompson C, Messersmith W. Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2011 Sep 6. [Epub ahead of print].
24. Messersmith, W. KRAS: Guiding Treatment of Patients with Metastatic Colorectal Cancer. *Clin Adv Hem Onc* 2011;9(10):760-762.
25. Weickhardt A, Wells K, Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. *J Oncol*. 2011;2011:201593. Epub 2011 Dec 12
26. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol*. 2012 Apr 17. doi: 10.1038/nrclinonc.2012.61. [Epub ahead of print]
27. Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. *Drugs Today (Barc)*. 2013 Feb;49(2):105-15.
28. Scott A, Messersmith WA, Jimeno A, Davies SL. Panitumumab in the treatment of colon cancer: A biomarker dilemma. *Drugs Today (Barc)*. 2014 Oct;50(10):679-90.
29. Singh S, Arcaroli J, Thompson DC, Messersmith W, Vasiliou V. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. *Adv Exp Med Biol*. 2015;815:281-94.
30. Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. *Drugs Today (Barc)*. 2015 Apr;51(4):223-9.
31. Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH. Targeting the WNT Signaling Pathway in Cancer Therapeutics. *Oncologist*. 2015 Oct;20(10):1189-98.
32. Scott AJ, Lieu CH, Messersmith WA. Therapeutic Approaches to RAS Mutation. *Cancer J*. 2016 May-Jun;22(3):165-74.
33. Lieu CH and Messersmith WA. Cetuximab or bevacizumab with first-line chemotherapy in advanced KRAS wild-type colorectal cancer: no difference, but not the same. *JAMA* 2017

34. Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. *Cancer Immunol Res*. 2017 Nov;5(11):942-949
35. Wani S, Muthusamy VR, McGrath CM, Sepulveda AR, Das A, Messersmith W, Kochman ML, Shah J. AGA White Paper: Optimizing Endoscopic Ultrasound-Guided Tissue Acquisition and Future Directions. *Clin Gastroenterol Hepatol*. 2017 Oct 23.
36. Weiss J, Glode A, Messersmith WA, Diamond J. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. *Expert Rev Anticancer Ther*. 2019 Aug 19.
37. Messersmith WA, Systemic Management of Colorectal Cancer. *J Natl Compr Canc Netw* 2017 May;15(5S):699-702
38. Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. *Cancer Immunol Res*. 2017 Nov;5(11):942-949.
39. Messersmith WA, NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer. *J Natl Compr Canc Netw*. 2019 May 1;17(5.5):599-601
40. Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology? *Mol Cancer Ther*. 2021 Apr 13.
41. Lentz RW, Messersmith WA. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. *J Clin Oncol*. 2021 Sep 20
42. Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. *J Gastrointest Oncol*. 2021 Oct;12(5):2461-2474.
43. Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. *BMJ*. 2023 Dec 13;383:e073995.
44. Robinson HR, Messersmith WA, Lentz RW. HER2-Positive Metastatic Colorectal Cancer. *Curr Treat Options Oncol*. 2024 Mar 28.
45. Kummar S, Bui N, Messersmith WA, Whiting J, Portnoy M, Lim A, Mary L. Nirogacestat: the pathway to approval of the first treatment for desmoid tumors, a rare disease. *Ther Adv Rare Dis*. 2025 Feb 11
46. Ueberroth BE, Kriss M, Burton JR Jr, Messersmith WA. Liver transplantation for colorectal cancer with liver metastases. *Oncologist*. 2025 Jan 17;30(1).
47. Khomiak A, Balmaceda NB, Ghaffar SA, Lieu CH, Del Chiaro M, Messersmith WA, Lentz RW. Oligometastatic pancreatic cancer: current state of management and emerging therapies. *Oncologist*. 2025 Jun 4;30(6):oyaf154

BOOK CHAPTERS

1. Messersmith WA, Laheru DA, Abrams R: Adjuvant Therapy for Pancreatic Cancer. DeVita VT, Hellman S and Rosenberg SA, eds. *Cancer. Principles and Practice of Oncology* 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2004.
2. Infante J and Messersmith WA, Adjuvant therapy for Colorectal Cancer. John Cameron, Ed. *Advances in Surgery*, 9th edition, 2008. Mosby Elsevier (Philadelphia, PA).
3. Infante J and Messersmith WA, Prognosis and Follow-Up of Pancreas Cancer. Jankowski J, Sampliner R, Kelt O, and Fong Y, eds. *Gastrointestinal Oncology: A Critical MDT Approach*. Blackwell Publishing (Oxford), 2007 (in press).

4. Ma WW and Messersmith WA. Medical management of colorectal liver metastases. In Geschwind JF and Soulen C, eds. *Interventional Oncology*. Cambridge University Press, 2008.
5. Schwartz R, Goolsby T, and Messersmith WA. Overview of Chemotherapy. In Geschwind JF and Soulen C, eds. *Interventional Oncology*. Cambridge University Press, 2008.
6. El-Shami K, Nallapareddy S, and Messersmith WA. Chemotherapy for Colorectal Cancer. In Gearhart S and Ahuja N, eds. *Early Diagnosis of Cancer: Colon Cancer* (Saunders Elsevier, Philadelphia, PA), 2011.
7. Ma WW and Messersmith WA. Lower Gastrointestinal Cancer. In Donehower R and Ettinger D, eds. *Current Cancer Therapeutics (5th Ed)*. Current Medicine Group, LLC (Springer), 2009.
8. Reidy-Lagunes D, Lieu CH, Messersmith WA, and Goodman K, *Uncommon Tumors of the Colon and Rectum, Textbook of Uncommon Cancer*, Edited by Derek Raghavan et al. (2017)

MAGAZINE ARTICLES

1. Messersmith WA, “Case-Based Peer Perspectives: Colorectal Cancer” *Targeted Therapies* 2017 Volume 6/No. 10; 81-82.

LETTERS TO THE EDITOR

1. Lieu C, Sorkin A, and Messersmith WA, “Right to Try?” *J Clin Oncol*. 2015 Mar 16.

ONLINE REFERENCES

1. Dasari A and Messersmith WA, “Colorectal Cancer: What Every Physician Needs to Know”. *Clinical Decision Support Online* 2012; 2014 (Johnson, Benz, Gerber, LaCasce, ed).

NCCN GUIDELINES (published yearly; on 3 panels since 2014; listing only the most recent guidelines)

1. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. Share. **NCCN Guidelines Insights: Rectal Cancer**, Version 3.2024. *J Natl Compr Canc Netw* 2024;22(6):366–375.
2. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. **Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology** *J Natl Compr Canc Netw* 2019 Sep 1;17(9):1109-1133
2. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, PedersennerK, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. **Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology**. *J Natl Compr Canc Netw*. 2023 Jun;21(6):653-677. PMID: 37308125

3. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. **Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology**. J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359.. PMID: 33724754

PODCASTS

1. Messersmith W, "Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab" by Sabine Tejpar, et al." Journal of Clinical Oncology (8/27/2012)
2. ASCO Journal Club: Gastrointestinal Cancers (9/24/2015 launch). Discussion of TAS-102, MSI-H colorectal cancer, and salvage surgery for esophagectomy.

BOOKS

1. Basch E, Birnbaum S, Garza C, and Messersmith WA, Editors. MGH Primer of Outpatient Medicine. Philadelphia: Lippincott, Williams, and Wilkins; 2002.

PERSONAL

- Coach (parent volunteer), Storm/Rapids Soccer Club; Skyline Soccer Club 2008-2020
- Coach (parent volunteer), YMCA and i9 basketball, 2015-2021
- Coach (parent volunteer), NFL Youth Flag Football 2021-2023
- Volunteer, Boys Team Charity (2020-present)